Help
RSS
API
Feed
Maltego
Contact
Domain > ins1.caboodleai.net
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
Whois
Property
Value
Email
caboodleai.net@domainsbyproxy.com
NameServer
NS-124.AWSDNS-15.COM
Created
2020-05-05 12:42:48
Changed
2020-07-06 07:02:12
Registrar
GoDaddy.com, LLC
DNS Resolutions
Date
IP Address
2022-09-26
23.48.210.99
(
ClassC
)
2025-01-26
23.38.191.178
(
ClassC
)
Port 443
HTTP/1.1 200 OKContent-Type: text/html; charsetutf-8X-Check-Cacheable: YESx-next-pathname: /Cache-Control: private, no-cache, no-store, must-revalidateDate: Sun, 26 Jan 2025 10:17:27 GMTTransfer-Encoding: chunkedConnection: keep-aliveConnection: Transfer-Encoding !DOCTYPE html>html langen>head>meta charSetutf-8/>meta nameviewport contentwidthdevice-width/>title>INS/title>meta propertydescription contentThe #1 newsfeed for the INS industry. Bringing you the best content from thousands of sources, covering product, research, trends, and more. Pick your industry interests and stay up-to-date with the most relevant news to your business./>meta propertyog:type contentwebsite/>meta propertyog:locale contenten_US/>meta propertyog:title contentINS/>meta propertyog:image contenthttps://media.caboodleai.net/ins1/general/74c824493f794bd89c4c55e35976b27a-01a384a4dcd44bfab356e227683235dc-INS_New_Header__LOGO-165X63.jpg/>meta propertyog:image:width content500/>meta propertyog:image:height content100/>meta propertyog:description contentThe #1 newsfeed for the INS industry. Bringing you the best content from thousands of sources, covering product, research, trends, and more. Pick your industry interests and stay up-to-date with the most relevant news to your business./>meta propertyrobots contentindex, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1 noimageindex/>meta propertytwitter:card contentsummary_large_image/>meta propertytwitter:image contenthttps://media.caboodleai.net/ins1/general/74c824493f794bd89c4c55e35976b27a-01a384a4dcd44bfab356e227683235dc-INS_New_Header__LOGO-165X63.jpg/>meta propertytwitter:image:alt contentINS/>meta propertytwitter:title contentINS/>meta propertytwitter:description contentThe #1 newsfeed for the INS industry. Bringing you the best content from thousands of sources, covering product, research, trends, and more. Pick your industry interests and stay up-to-date with the most relevant news to your business./>link relcanonical hrefhttps://ins1.caboodleai.net//>script typeapplication/ld+json>{ @context: https://schema.org/, @type: WebSite, name: INS, url: https://ins1.caboodleai.net/, potentialAction: { @type: ReadAction, target:https://ins1.caboodleai.net/ } } /script>link relicon typeimage/png hrefhttps://media.caboodleai.net/ins1/general/f7e5e8452cc64744a25c2e3ab182a96c-caboodle_favicon.ico/>script idtag-manager>(function(w,d,s,l,i){wlwl||;wl.push({gtm.start: new Date().getTime(),event:gtm.js});var fd.getElementsByTagName(s)0, jd.createElement(s),dll!dataLayer?&l+l:;j.asynctrue;j.src https://www.googletagmanager.com/gtm.js?id+i+dl;f.parentNode.insertBefore(j,f); })(window,document,script,dataLayer,GTM-5VF5P92);/script>meta namenext-head-count content21/>link data-next-font relpreconnect href/ crossoriginanonymous/>link relpreload href/_next/static/css/ae6a727f20c5d4ca.css asstyle/>link relstylesheet href/_next/static/css/ae6a727f20c5d4ca.css data-n-g/>link relpreload href/_next/static/css/ee61a0d44b34fa85.css asstyle/>link relstylesheet href/_next/static/css/ee61a0d44b34fa85.css/>noscript data-n-css>/noscript>script defer nomodule src/_next/static/chunks/polyfills-78c92fac7aa8fdd8.js>/script>script defer src/_next/static/chunks/9731.482cdef36e917d18.js>/script>script defer src/_next/static/chunks/7365.06ad2c45df91721b.js>/script>script defer src/_next/static/chunks/9345.d6d095472a7cab64.js>/script>script defer src/_next/static/chunks/2546.c1df938cd182e4cd.js>/script>script defer src/_next/static/chunks/2894.8afeec78fb06cb17.js>/script>script defer src/_next/static/chunks/698.a495cecdf1cc5de1.js>/script>script defer src/_next/static/chunks/4843.9e49383bf09dc358.js>/script>script defer src/_next/static/chunks/1664-d16b4c696e3582c4.js>/script>script defer src/_next/static/chunks/5675-b6cbad223d732a54.js>/script>script defer src/_next/static/chunks/9703.1b1c672a7520a8e8.js>/script>script defer src/_next/static/chunks/4123.270ff19bc235d5d3.js>/script>script src/_next/static/chunks/webpack-64d349881f1a075a.js defer>/script>script src/_next/static/chunks/framework-5f3bd70902f3793a.js defer>/script>script src/_next/static/chunks/main-07193ddb7d5203f4.js defer>/script>script src/_next/static/chunks/pages/_app-524e096f3a7e8bc2.js defer>/script>script src/_next/static/chunks/pages/index-8b745365bd3a7971.js defer>/script>script src/_next/static/1734289630900/_buildManifest.js defer>/script>script src/_next/static/1734289630900/_ssgManifest.js defer>/script>/head>body>div id__next> noscript>iframe srchttps://www.googletagmanager.com/ns.html?idGTM-5VF5P92 height0 width0 styledisplay:none;visibility:hidden>/iframe>/noscript> !-- --> !-- --> /div>script id__NEXT_DATA__ typeapplication/json>{props:{pageProps:{articles:{articleType:7,previewText:SAN FRANCISCO -- Three-fourths of patients with unresectable gastroesophageal cancer converted to resectable and had clear margins after treatment with a chemoimmunotherapy combination, a small Chinese study showed.\nResults showed that 39 of 52 patients had clear margins (R0) after surgery, following treatment with the PD-1 antibody camrelizumab an,relevancy:0.59634286,approvalType:1,language:en,companyName:MedPage Today,companyId:10976,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-25T14:21:44.517,companyLogoUrl:companies/95a91d35-4d73-4035-b019-b6f42aac6f8f.com.png,companyLogoDominantColor:#00235F,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:1,labelsCount:7,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:638},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:manual,allArticlesApproved:0,companySiteUrl:http://www.medpagetoday.com,isManualOrdering:false,layoutId:0,articleId:228951,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/7ca41d73-28ed-4fc9-8b86-0e003e124440.jpg,publicationDate:2025-01-24T00:00:00,title:High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer,openMode:1,uri:https://www.medpagetoday.com/meetingcoverage/mgics/113922,domainUrl:medpagetoday.com,isSponsored:false,articleUrl:article/228951/high-success-rate-with-conversion-therapy-for-unresectable-gastroesophageal-cancer},{articleType:7,previewText:The FDA has approved treosulfan (Grafapex) in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).1\nThe regulatory decision was supported by data from the pha,relevancy:0.8832593,approvalType:1,language:en,companyName:OncLive,companyId:11146,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-25T14:22:36.12,companyLogoUrl:companies/f13ae382-0032-4e43-9db7-5027771290db.com.png,companyLogoDominantColor:#C2E3F3,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:2,labelsCount:3,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:724},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:tile,allArticlesApproved:0,companySiteUrl:http://www.onclive.com,isManualOrdering:false,layoutId:0,articleId:228958,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/bb11f14e-269a-4621-8a12-3208d0ac114f.jpg,publicationDate:2025-01-24T00:00:00,title:FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS,openMode:1,uri:https://www.onclive.com/view/fda-approves-treosulfan-for-allohct-conditioning-in-aml-and-mds,domainUrl:onclive.com,isSponsored:false,articleUrl:article/228958/fda-approves-treosulfan-for-allohct-conditioning-in-aml-and-mds},{articleType:7,previewText:In 2015, fungal infections affected over 1 billion people globally each year, leading to an estimated 11.5 million life-threatening infections and more than 1.5 million deaths annually. Despite their significant impact, fungal diseases have historically been under-recognized and underfunded in global health efforts. In response, the Global Action F,relevancy:0.8233331,approvalType:1,language:en,companyName:ContagionLive,companyId:12956,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-24T14:17:50.95,companyLogoUrl:companies/a11d9e5a-b44b-4e0f-998d-904760217e74.com.png,companyLogoDominantColor:#FFFFFF,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:3,labelsCount:2,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:766},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:tile,allArticlesApproved:0,companySiteUrl:http://www.contagionlive.com,isManualOrdering:false,layoutId:0,articleId:228880,statusId:1,thumbnailUrl:null,publicationDate:2025-01-24T00:00:00,title:Fungal Infections: Invisible Until Its Too Late,openMode:1,uri:https://www.contagionlive.com/view/fungal-infections-invisible-until-it-s-too-late,domainUrl:contagionlive.com,isSponsored:false,articleUrl:article/228880/fungal-infections-invisible-until-its-too-late},{articleType:7,previewText:Combining transarterial chemoembolization (TACE) with camrelizumab and rivoceranib (apatinib) elicited a clinically meaningful and statistically significant progression-free survival (PFS) improvement among patients with unresectable hepatocellular carcinoma (HCC), according to data from the phase 2 CARES-005 study (NCT04559607) presented at the 20,relevancy:0.8811526,approvalType:1,language:en,companyName:Cancer Network,companyId:13468,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-25T14:21:12.667,companyLogoUrl:companies/381a84fd-22ed-45f7-a011-f9c855892ee6.com.png,companyLogoDominantColor:#FFFFFF,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:4,labelsCount:2,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:832},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:tile,allArticlesApproved:0,companySiteUrl:http://www.cancernetwork.com,isManualOrdering:false,layoutId:0,articleId:228945,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/da973b60-b240-4216-85f1-089b9dd1e38d.jpg,publicationDate:2025-01-24T00:00:00,title:TACE Plus Camrelizumab/Rivoceranib Extends PFS in Unresectable Liver Cancer,openMode:1,uri:https://www.cancernetwork.com/view/tace-plus-camrelizumab-rivoceranib-extends-pfs-in-unresectable-liver-cancer,domainUrl:cancernetwork.com,isSponsored:false,articleUrl:article/228945/tace-plus-camrelizumabrivoceranib-extends-pfs-in-unresectable-liver-cancer},{articleType:7,previewText:An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade 3 (CIN3), according to results from a small phase II study.\nTreatment with Vvax001 -- comprised of replication-deficient recombinant Semliki Forest virus particles encoding a fusion pro,relevancy:0.6355132,approvalType:1,language:en,companyName:MedPage Today,companyId:10976,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-25T14:21:43.91,companyLogoUrl:companies/95a91d35-4d73-4035-b019-b6f42aac6f8f.com.png,companyLogoDominantColor:#00235F,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:5,labelsCount:1,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:577},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:tile,allArticlesApproved:0,companySiteUrl:http://www.medpagetoday.com,isManualOrdering:false,layoutId:0,articleId:228949,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/8df7f4cf-a1b5-4fc9-98be-db4887aa601c.jpg,publicationDate:2025-01-24T00:00:00,title:Therapeutic HPV Vaccine Effective in Reducing Precancerous Cervical Lesions,openMode:1,uri:https://amp.medpagetoday.com/obgyn/cervicalcancer/113928,domainUrl:medpagetoday.com,isSponsored:false,articleUrl:article/228949/therapeutic-hpv-vaccine-effective-in-reducing-precancerous-cervical-lesions},{articleType:7,previewText:The addition of sintilimab (Tyvyt) to neoadjuvant chemoradiotherapy (CRT) led to an improvement in pathological complete response (pCR) rate compared with CRT alone in patients with resectable, locally advanced esophageal squamous cell carcinoma (ESCC), according to preliminary data from the phase 3 SCIENCE trial (NCT05244798) presented at the 2025,relevancy:0.8605926,approvalType:1,language:en,companyName:OncLive,companyId:11146,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-25T14:22:35.807,companyLogoUrl:companies/f13ae382-0032-4e43-9db7-5027771290db.com.png,companyLogoDominantColor:#C2E3F3,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:6,labelsCount:4,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:1088},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:tile,allArticlesApproved:0,companySiteUrl:http://www.onclive.com,isManualOrdering:false,layoutId:0,articleId:228957,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/1ccf29b3-28eb-4f46-92a9-e56a99ebb70e.png,publicationDate:2025-01-24T00:00:00,title:Neoadjuvant Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC,openMode:1,uri:https://www.onclive.com/view/neoadjuvant-sintilimab-plus-chemoradiotherapy-improves-pcr-rate-in-resectable-locally-advanced-escc,domainUrl:onclive.com,isSponsored:false,articleUrl:article/228957/neoadjuvant-sintilimab-plus-chemoradiotherapy-improves-pcr-rate-in-resectable-locally-advanced-escc},{articleType:7,previewText:In findings published this week, the investigational therapy, VE303, which is being developed for recurrent Clostridioides difficile infection (rCDI) demonstrated it was able to reduce the chance of recurrence by more than 80% compared to placebo in its phase 2 CONSORTIUM study.1\n“Due to VE303’s precisely known, defined composition, we can study it,relevancy:0.8499193,approvalType:1,language:en,companyName:ContagionLive,companyId:12956,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-25T14:20:13.23,companyLogoUrl:companies/a11d9e5a-b44b-4e0f-998d-904760217e74.com.png,companyLogoDominantColor:#FFFFFF,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:7,labelsCount:0,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:616},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:tile,allArticlesApproved:0,companySiteUrl:http://www.contagionlive.com,isManualOrdering:false,layoutId:0,articleId:228939,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/915a2e7c-1568-46a2-b64c-4ed82c0bdcb0.jpg,publicationDate:2025-01-24T00:00:00,title:Investigational Live Biotherapeutic Product Significantly Reduces Risk of Recurrent Clostridioides difficile,openMode:1,uri:https://www.contagionlive.com/view/investigational-live-biotherapeutic-product-significantly-reduces-risk-of-recurrent-clostridioides-difficile,domainUrl:contagionlive.com,isSponsored:false,articleUrl:article/228939/investigational-live-biotherapeutic-product-significantly-reduces-risk-of-recurrent-clostridioides-difficile},{articleType:7,previewText:To the Editor: Bullous pemphigoid (BP) is a rare autoimmune skin disorder characterized by significant mortality, with BP prevalence ranging from 1.46 to 47.99 cases per 100,000 people.1 The pathogenic mechanism of BP is attributed to pathogenic autoantibodies targeting BP180 and BP230 antigens, resulting in the formation of subepidermal blisters,relevancy:0.5427042,approvalType:1,language:en,companyName:LWW Journals,companyId:12344,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-23T14:16:28.383,companyLogoUrl:companies/31419a1b-b7ff-4ca4-aff1-6e261a2271e6.com.png,companyLogoDominantColor:#FFFFFF,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:11,labelsCount:0,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:1258},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:list-large,allArticlesApproved:0,companySiteUrl:http://journals.lww.com,isManualOrdering:false,layoutId:0,articleId:228799,statusId:1,thumbnailUrl:null,publicationDate:2025-01-23T00:00:00,title:Bullous pemphigoid with anti-desmoglein antibodies: An incident of coincidence or not?,openMode:1,uri:https://journals.lww.com/cmj/fulltext/9900/bullous_pemphigoid_with_anti_desmoglein.1407.aspx,domainUrl:journals.lww.com,isSponsored:false,articleUrl:article/228799/bullous-pemphigoid-with-antidesmoglein-antibodies-an-incident-of-coincidence-or-not?},{articleType:7,previewText:Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to concerns of increased risk of bleeding complications.\nResearchers from Mass General Brigham evaluated a drug that represents a new class of anticoagulants k,relevancy:0.51115656,approvalType:1,language:en,companyName:Medical Xpress,companyId:10980,isCompanyApproved:0,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-24T14:15:34.793,companyLogoUrl:companies/42024709-ea22-4ba2-9dfc-0533732f7c3b.com.png,companyLogoDominantColor:#FFFFFF,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:8,labelsCount:2,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:550},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:list-large,allArticlesApproved:0,companySiteUrl:http://medicalxpress.com,isManualOrdering:false,layoutId:0,articleId:228854,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/959f463c-09b9-46e4-af4e-dad25c7c9bdc.jpg,publicationDate:2025-01-23T00:00:00,title:Anti-clotting drug significantly reduces bleeding events in patients with atrial fibrillation, clinical trial shows,openMode:0,uri:https://medicalxpress.com/news/2025-01-anti-clotting-drug-significantly-events.html,domainUrl:medicalxpress.com,isSponsored:false,articleUrl:article/228854/anticlotting-drug-significantly-reduces-bleeding-events-in-patients-with-atrial-fibrillation-clinical-trial-shows},{articleType:7,previewText:1. Early DOAC therapy within 4 days was non-inferior to delayed therapy for the composite outcome of recurrent ischemic or unclassified stroke, symptomatic intracranial hemorrhage, and systemic embolism at 90 days.\nEvidence Rating Level: 1 (Excellent)\nStudy Rundown: The optimal timing for starting anticoagulation in patients with acute ischemic str,relevancy:0.88209033,approvalType:1,language:en,companyName:2 Minute Medicine,companyId:11002,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-24T09:24:00.387,companyLogoUrl:companies/bbb7df92-b982-4e7c-8fb5-fd2b76044375.com.png,companyLogoDominantColor:#000000,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:9,labelsCount:3,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:369},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:list-large,allArticlesApproved:0,companySiteUrl:http://www.2minutemedicine.com,isManualOrdering:false,layoutId:0,articleId:228818,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/858338c2-488d-4572-8532-31c05c63d609.jpg,publicationDate:2025-01-23T00:00:00,title:#VisualAbstract Early Oral Anticoagulation is Non-inferior to Delayed Treatment in Patients with Ischemic Stroke and Atrial Fibrillation,openMode:1,uri:https://www.2minutemedicine.com/67920-2/?amp_markup1,domainUrl:2minutemedicine.com,isSponsored:false,articleUrl:article/228818/visualabstract-early-oral-anticoagulation-is-noninferior-to-delayed-treatment-in-patients-with-ischemic-stroke-and-atrial-fibrillation},{articleType:7,previewText:Commentary\nVideo\nJanuary 23, 2025\nAuthor(s):\nTalha Badar, MBBS, MD\nJavier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.\nRelated Videos\nHighlighting Key CML/ALL Data Presented at ASH 2024\nEmerging Mutation Analysis from the OPTIC Trial\nHodgkin Lymphoma: Overview and Update\nFrontline Treatment Co,relevancy:0.8491876,approvalType:1,language:en,companyName:OncLive,companyId:11146,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-24T14:15:37.243,companyLogoUrl:companies/f13ae382-0032-4e43-9db7-5027771290db.com.png,companyLogoDominantColor:#C2E3F3,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:10,labelsCount:4,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:246},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:list-large,allArticlesApproved:0,companySiteUrl:http://www.onclive.com,isManualOrdering:false,layoutId:0,articleId:228859,statusId:1,thumbnailUrl:null,publicationDate:2025-01-23T00:00:00,title:Dosing Strategies for Ponatinib in CML and ALL,openMode:1,uri:https://www.onclive.com/view/dosing-strategies-for-ponatinib-in-cml-and-all,domainUrl:onclive.com,isSponsored:false,articleUrl:article/228859/dosing-strategies-for-ponatinib-in-cml-and-all},{articleType:7,previewText:Afrigen Biologics, a South African biotechnology company, has secured a $6.2 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop the first mRNA-based vaccine for Rift Valley fever (RVF). This funding will advance the vaccine candidate through preclinical development and into Phase I clinical trials, with testing,relevancy:0.82032996,approvalType:1,language:en,companyName:ContagionLive,companyId:12956,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-23T14:15:59.043,companyLogoUrl:companies/a11d9e5a-b44b-4e0f-998d-904760217e74.com.png,companyLogoDominantColor:#FFFFFF,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:12,labelsCount:3,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:795},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:list-large,allArticlesApproved:0,companySiteUrl:http://www.contagionlive.com,isManualOrdering:false,layoutId:0,articleId:228795,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/7a9da866-ea89-4acd-a714-c49ee7bd3e9b.png,publicationDate:2025-01-23T00:00:00,title:Timeline for mRNA Vaccine Development for Rift Valley Fever,openMode:1,uri:https://www.contagionlive.com/view/timeline-for-mrna-vaccine-development-for-rift-valley-fever,domainUrl:contagionlive.com,isSponsored:false,articleUrl:article/228795/timeline-for-mrna-vaccine-development-for-rift-valley-fever},{articleType:7,previewText:A CD47 myeloid checkpoint inhibitor, evorpacept (ALX148), in combination with trastuzumab (Herceptin), paclitaxel, and ramucirumab (Cyramza; TRP) elicited favorable survival outcomes and responses compared with TRP alone in patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer, according to findings from the phase 2/3 ASPEN-,relevancy:0.8717099,approvalType:1,language:en,companyName:Cancer Network,companyId:13468,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-24T14:15:35.57,companyLogoUrl:companies/381a84fd-22ed-45f7-a011-f9c855892ee6.com.png,companyLogoDominantColor:#FFFFFF,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:13,labelsCount:1,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:782},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:list-large,allArticlesApproved:0,companySiteUrl:http://www.cancernetwork.com,isManualOrdering:false,layoutId:0,articleId:228856,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/54b27609-66f4-4a42-81e0-c4f53ad4dcdf.jpg,publicationDate:2025-01-23T00:00:00,title:Evorpacept Elicits Favorable Responses in HER2+ Gastric/GEJ Cancer,openMode:1,uri:https://www.cancernetwork.com/view/evorpacept-elicits-favorable-responses-in-her2-gastric-gej-cancer,domainUrl:cancernetwork.com,isSponsored:false,articleUrl:article/228856/evorpacept-elicits-favorable-responses-in-her2-gastricgej-cancer},{articleType:7,previewText:CEO of Afrigen.\nArticles\nTimeline for mRNA Vaccine Development for Rift Valley Fever\nSophia Abene;Petro Terblanche;Caryn Fenner\nCaryn Fenner and Petro Terblanche outline Afrigens clinical trial plans, local partnerships, and vaccine pipeline.\nRead More\nAfrigen Biologics Advancing Development of mRNA Vaccine for Rift Valley Fever\nSophia Abene;Caryn,relevancy:0.81604236,approvalType:1,language:en,companyName:ContagionLive,companyId:12956,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-23T14:15:58.82,companyLogoUrl:companies/a11d9e5a-b44b-4e0f-998d-904760217e74.com.png,companyLogoDominantColor:#FFFFFF,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:14,labelsCount:2,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:200},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:list-large,allArticlesApproved:0,companySiteUrl:http://www.contagionlive.com,isManualOrdering:false,layoutId:0,articleId:228794,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/a2be400a-d60e-4ffe-8618-4c9b26261d75.png,publicationDate:2025-01-23T00:00:00,title:Petro Terblanche,openMode:1,uri:https://www.contagionlive.com/authors/petro-terblanche,domainUrl:contagionlive.com,isSponsored:false,articleUrl:article/228794/petro-terblanche},{articleType:7,previewText:Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with extensive vitiligo see significantly more repigmentation compared with a placebo group in a \proof-of-concept\ trial, researchers said.\nPatients assigned to the drug saw a mean decrease in Vitiligo Area Scoring Index (VASI) valu,relevancy:0.52215177,approvalType:1,language:en,companyName:MedPage Today,companyId:10976,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-23T14:15:46.65,companyLogoUrl:companies/95a91d35-4d73-4035-b019-b6f42aac6f8f.com.png,companyLogoDominantColor:#00235F,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:15,labelsCount:5,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:669},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:list-large,allArticlesApproved:0,companySiteUrl:http://www.medpagetoday.com,isManualOrdering:false,layoutId:0,articleId:228775,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/565895ec-2355-416e-8164-b2eb5a97d601.jpg,publicationDate:2025-01-22T00:00:00,title:Targeted Oral Drug Plus UV Therapy May Help in Extensive Vitiligo,openMode:1,uri:https://www.medpagetoday.com/dermatology/generaldermatology/113876,domainUrl:medpagetoday.com,isSponsored:false,articleUrl:article/228775/targeted-oral-drug-plus-uv-therapy-may-help-in-extensive-vitiligo},{articleType:7,previewText:The American Gastroenterological Association (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation (HBVr) in patients on immunosuppressive drugs. The use of immunosuppressive drugs has increased significantly since 2013, according to data gathered via,relevancy:0.6900761,approvalType:1,language:en,companyName:News-Medical.net,companyId:10999,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-24T14:15:37.853,companyLogoUrl:companies/a7a12191-c7b5-420d-bc0e-7154cf3c2265.net.png,companyLogoDominantColor:#125E8A,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:16,labelsCount:1,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:684},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:list-large,allArticlesApproved:0,companySiteUrl:http://www.news-medical.net,isManualOrdering:false,layoutId:0,articleId:228861,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/6ff638c9-50fc-47fe-b6e2-bca2a24eed7e.jpg,publicationDate:2025-01-22T00:00:00,title:AGA releases updated guidelines on hepatitis B reactivation in patients on immunosuppressive drugs,openMode:1,uri:http://www.news-medical.net/news/20250123/AGA-releases-updated-guidelines-on-hepatitis-B-reactivation-in-patients-on-immunosuppressive-drugs.aspx,domainUrl:news-medical.net,isSponsored:false,articleUrl:article/228861/aga-releases-updated-guidelines-on-hepatitis-b-reactivation-in-patients-on-immunosuppressive-drugs},{articleType:7,previewText:SHR-A1811, a third-generation antibody-drug conjugate, demonstrated antitumor activity and manageable safety in the treatment of heavily pretreated patients with HER2-positive and HER2-low breast cancer, as well as other HER2-expressing or -mutated solid tumors, according to results from the phase 1 SHR-A1811-I-101 trial (NCT04446260) presented dur,relevancy:0.84097975,approvalType:1,language:en,companyName:OncLive,companyId:11146,isCompanyApproved:1,isCompanyActive:0,subTitle:null,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-23T14:15:52.5,companyLogoUrl:companies/f13ae382-0032-4e43-9db7-5027771290db.com.png,companyLogoDominantColor:#C2E3F3,publishedRank:1,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:17,labelsCount:2,additionalData:{totalFacebookShares:0,totalLinkedInShares:0,totalTwitterShares:0,totalEmailShares:0,totalShares:0,wordsCount:866},contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:list-large,allArticlesApproved:0,companySiteUrl:http://www.onclive.com,isManualOrdering:false,layoutId:0,articleId:228788,statusId:1,thumbnailUrl:https://media.caboodleai.net/ins1/19a/f0b33d91-3fe2-4280-8d6e-e2b5e57213f7.webp,publicationDate:2025-01-22T00:00:00,title:SHR-A1811 Maintains Efficacy, Safety in Pretreated HER2-Expressing/-Mutated Breast Cancer, Other Solid Tumors,openMode:1,uri:https://www.onclive.com/view/shr-a1811-maintains-efficacy-safety-in-pretreated-her2-expressing--mutated-breast-cancer-other-solid-tumors,domainUrl:onclive.com,isSponsored:false,articleUrl:article/228788/shra1811-maintains-efficacy-safety-in-pretreated-her2expressingmutated-breast-cancer-other-solid-tumors},settings:{keyName:DateFormat,value:MMMM Do YYYY,description:null},{keyName:GatedIvKey,value:1234567890123456,description:null},{keyName:GatedKey,value:1234567890123456,description:null},{keyName:AdvertisementButtonText,value:Advertise In This Industry Newsfeed,description:null},{keyName:AdvertisementsLikeCarousel,value:true,description:null},{keyName:GoogleAnalyticsCustomerAccount,value:,description:null},{keyName:GTM_Key,value:,description:null},{keyName:SiteDisplayName,value:{\Pairs\:{\Key\:\en\,\Value\:\INS\}},description:null},{keyName:PrivacyPolicyUrl,value:https://ins1.caboodleai.net/feed/policy,description:null},{keyName:CookiePolicyUrl,value:https://ins1.caboodleai.net/feed/terms,description:null},{keyName:IsArticleAutomaticApprovalEnabled,value:true,description:null},{keyName:IsArticleAutomaticApprovalByCompanyEnabled,value:true,description:null},{keyName:IsArticleAutomaticApprovalBySourceEnabled,value:true,description:null},{keyName:TopBannerDesktop,value:general\\0b562f72ed7f475ab5abed91c2ceeff2-af6523f7a87a4e259d9a9c2dd02b6a10-INS_New_Header__NF-1140x138-(1).jpg,description:null},{keyName:Meta,value:The #1 newsfeed for the {0} industry. Bringing you the best content from thousands of sources, covering product, research, trends, and more. Pick your industry interests and stay up-to-date with the most relevant news to your business.,description:null},{keyName:TopBannerTablet,value:general\\f3b85deb4a444c45b49349015c025834-ade603c085f5483b8db203d23bf6f0ef-INS_New_Header__IG-720x138.jpg,description:null},{keyName:TopBannerMobile,value:general\\7ad9ac2ca6784c6095af0f7f7bb3e0de-67f2771f96d447a3a9b74f747dd82099-INS_New_Header__NF-449x138.jpg,description:null},{keyName:MainBannerLink,value:{\Pairs\:{\Key\:\en\,\Value\:null},{\Key\:\zh\,\Value\:null},{\Key\:\de\,\Value\:null},{\Key\:\fr\,\Value\:null}},description:null},{keyName:IsBunnerShowInNewsfeed,value:true,description:null},{keyName:LinkedInUrl,value:null,description:null},{keyName:TwitterUrl,value:null,description:null},{keyName:FacebookUrl,value:null,description:null},{keyName:YoutubeUrl,value:null,description:null},{keyName:InstagramUrl,value:null,description:null},{keyName:InstagramThreadsUrl,value:,description:null},{keyName:WhatsAppUrl,value:,description:null},{keyName:TiktokUrl,value:,description:null},{keyName:SharingHashtags,value:,description:null},{keyName:InstagramFeedUrl,value:{\Value\: \\, \Show\: false},description:null},{keyName:FacebookFeedUrl,value:{\Value\: \\, \Show\: false},description:null},{keyName:JobsUrl,value:{\Key\:\JobsUrl\,\Name\:\Jobs\,\Show\:0,\Value\:\\},description:null},{keyName:SubscriptionUrl,value:{\Key\:\SubscriptionUrl\,\Name\:\SUBSCRIBE FOR FREE\,\Show\:1,\Value\:\\},description:null},{keyName:ShowContentLibrary,value:1,description:null},{keyName:ShowPressRelease,value:1,description:null},{keyName:TrendingNowUrls,value:{\Pairs\:{\Key\:\ContactUrl\,\Name\: \Contact\, \Show\: 1,\Value\:\\},{\Key\:\AdvertiseUrl\,\Name\: \Advertise\, \Show\: 1,\Value\:\\},{\Key\:\OthersIndustriesUrl\,\Name\: \Other industries\, \Show\: 1,\Value\:\\}},description:null},{keyName:FavIcon,value:general\\f7e5e8452cc64744a25c2e3ab182a96c-caboodle_favicon.ico,description:null},{keyName:BackgroundImage,value:,description:null},{keyName:TopBackgroundImage,value:,description:null},{keyName:SubscriptionFormLogo,value:general\\74c824493f794bd89c4c55e35976b27a-01a384a4dcd44bfab356e227683235dc-INS_New_Header__LOGO-165X63.jpg,description:null},{keyName:SecondarySiteColor,value:#174884,description:null},{keyName:PrimarySiteColor,value:#0f4d81,description:null},{keyName:BackgroundColor,value:#ffffff,description:null},{keyName:AccentColor,value:#62bd91,description:null},{keyName:AllSourcesToOpenInPublishersSite,value:false,description:null},{keyName:ContactUsEmail,value:info@associationrevenuepartners.com,description:null},{keyName:InjectHtmlAtBodyEnd,value:,description:null},{keyName:InjectHtmlAtHead,value:,description:null},{keyName:MediaUrl,value:https://media.caboodleai.net/,description:null},{keyName:NF_ShowLabels,value:false,description:null},{keyName:InjectHtmlAtBodyStart,value:,description:null},{keyName:SiteNameId,value:ins1,description:},ad:,isNewsfeedAvailable:true,mappedSettings:{DateFormat:MMMM Do YYYY,GatedIvKey:1234567890123456,GatedKey:1234567890123456,AdvertisementButtonText:Advertise In This Industry Newsfeed,AdvertisementsLikeCarousel:true,GoogleAnalyticsCustomerAccount:,GTM_Key:,SiteDisplayName:{\Pairs\:{\Key\:\en\,\Value\:\INS\}},PrivacyPolicyUrl:https://ins1.caboodleai.net/feed/policy,CookiePolicyUrl:https://ins1.caboodleai.net/feed/terms,IsArticleAutomaticApprovalEnabled:true,IsArticleAutomaticApprovalByCompanyEnabled:true,IsArticleAutomaticApprovalBySourceEnabled:true,TopBannerDesktop:general\\0b562f72ed7f475ab5abed91c2ceeff2-af6523f7a87a4e259d9a9c2dd02b6a10-INS_New_Header__NF-1140x138-(1).jpg,Meta:The #1 newsfeed for the {0} industry. Bringing you the best content from thousands of sources, covering product, research, trends, and more. Pick your industry interests and stay up-to-date with the most relevant news to your business.,TopBannerTablet:general\\f3b85deb4a444c45b49349015c025834-ade603c085f5483b8db203d23bf6f0ef-INS_New_Header__IG-720x138.jpg,TopBannerMobile:general\\7ad9ac2ca6784c6095af0f7f7bb3e0de-67f2771f96d447a3a9b74f747dd82099-INS_New_Header__NF-449x138.jpg,MainBannerLink:{\Pairs\:{\Key\:\en\,\Value\:null},{\Key\:\zh\,\Value\:null},{\Key\:\de\,\Value\:null},{\Key\:\fr\,\Value\:null}},IsBunnerShowInNewsfeed:true,LinkedInUrl:null,TwitterUrl:null,FacebookUrl:null,YoutubeUrl:null,InstagramUrl:null,InstagramThreadsUrl:,WhatsAppUrl:,TiktokUrl:,SharingHashtags:,InstagramFeedUrl:{\Value\: \\, \Show\: false},FacebookFeedUrl:{\Value\: \\, \Show\: false},JobsUrl:{\Key\:\JobsUrl\,\Name\:\Jobs\,\Show\:0,\Value\:\\},SubscriptionUrl:{\Key\:\SubscriptionUrl\,\Name\:\SUBSCRIBE FOR FREE\,\Show\:1,\Value\:\\},ShowContentLibrary:1,ShowPressRelease:1,TrendingNowUrls:{\Pairs\:{\Key\:\ContactUrl\,\Name\: \Contact\, \Show\: 1,\Value\:\\},{\Key\:\AdvertiseUrl\,\Name\: \Advertise\, \Show\: 1,\Value\:\\},{\Key\:\OthersIndustriesUrl\,\Name\: \Other industries\, \Show\: 1,\Value\:\\}},FavIcon:general\\f7e5e8452cc64744a25c2e3ab182a96c-caboodle_favicon.ico,BackgroundImage:,TopBackgroundImage:,SubscriptionFormLogo:general\\74c824493f794bd89c4c55e35976b27a-01a384a4dcd44bfab356e227683235dc-INS_New_Header__LOGO-165X63.jpg,SecondarySiteColor:#174884,PrimarySiteColor:#0f4d81,BackgroundColor:#ffffff,AccentColor:#62bd91,AllSourcesToOpenInPublishersSite:false,ContactUsEmail:info@associationrevenuepartners.com,InjectHtmlAtBodyEnd:,InjectHtmlAtHead:,MediaUrl:https://media.caboodleai.net/,NF_ShowLabels:false,InjectHtmlAtBodyStart:,SiteNameId:ins1},templates:{PageFeedLanding:{__component:article_plates,type:manual,start:0,number:1,showTitle:false,articleType:recent,title:,params:{days:5}},{__component:article_plates,type:tile,start:1,number:6,showTitle:true,articleType:recent,title:Recent news},{__component:article_plates,type:list-large,start:7,number:10,showTitle:false,articleType:recent,title:},UnpublishedLanding:{type:manual,showTitle:false,articleType:recent,title:,start:0,number:1},{type:tile,start:0,number:15,showTitle:true,articleType:recent,title:Recent news},{type:list-large,start:16,number:10,showTitle:false,articleType:recent,title:},FeedLayout:{html:\u003cdiv id\site-header\ style\ position: sticky; top: 0; z-index: 999; \\u003e\u003c/div\u003e\u003cdiv id\site-main\\u003e\u003c/div\u003e\u003cdiv id\site-footer\\u003e\u003c/div\u003e,isTrending:false},RightSection1:{__component:create_company_button,ng-click:$ctrl.broadcast(toggleCreateCompanyPopup),#text:Add Your Company },{__component:advertise_button,ng-click:$ctrl.broadcast(openAdvertisePopup),#text:{{$ctrl.settings.advertisementButtonName}}},{__component:advertisement,options:{code: $ctrl.template.indexOf(Guide) \u003c 0 ? N-R : B-R, number: 5, displayType: $ctrl.settings.Portal.AdvertisementsLikeCarousel ? 1 : 0}},{__component:featured_products,hideDescription:true,ng-if:$ctrl.template !PageGuide},{__component:article_plates,type:list-compact,start:0,number:6,showTitle:true,articleType:saved,title:Saved news,ng-if:$ctrl.settings.cookiesModel.isAuthenticated()},{__component:article_plates,type:list-compact,start:1,number:6,showTitle:true,articleType:shared,title:Popular on social,params:{days:5}},{__component:article_plates,type:list-compact,start:0,number:7,showTitle:true,articleType:featured-content,title:Sponsored Articles},{__component:subscribe_user,display:true},{__component:personalize_items,number:6,entityTypes:7,8,9,10,openAsLinks:true,title:Featured Sources,ng-show:$ctrl.template.indexOf(Guide) \u003c 0},{__component:twitter,#text:Industry Tweets},{__component:article_plates,type:list-compact,start:0,number:6,showTitle:true,articleType:organizer-news,title:Organizer news},{__component:newsletter_archive,count:5},SiteHeader:{__component:navbar,options:{left:{html:\u003cspan idnavbar-mynewsfeed\u003e\u003c/span\u003e,name:My newsfeed,href:/tracker/mynewsfeed,target:_self},{html:\u003cspan idnavbar-home\u003e\u003c/span\u003e,name:Recent,href:/,target:_self},{html:\u003cspan idnavbar-buyersguide\u003e\u003c/span\u003e,name:Buyers Guide,href:/buyers-guide,target:_self},right:{html:\u003cspan idnavbar-login\u003e\u003c/span\u003e,name:Login,href:}}},SiteMain:{__component:site-banner},{__component:advertisement,options:{code:N-A,order:0,number:5}},{__component:feed,options:{trending:false}},{__component:right-panel},{__component:advertisement,options:{code:N-D,order:0,number:5}},SiteFooter:{__component:site-footer,options:{trending:false,fullWidth:true,styles:{background:black,color:white,margin:0px auto}}},BGRightPanel:{__component:create_company_button,ng-click:$ctrl.broadcast(toggleCreateCompanyPopup),#text:Add Your Company },{__component:advertise_button,ng-click:$ctrl.broadcast(openAdvertisePopup),#text:{{$ctrl.settings.advertisementButtonName}}},{__component:advertisement,options:{code: $ctrl.template.indexOf(Guide) \u003c 0 ? N-R : B-R, number: 5, displayType: $ctrl.settings.Portal.AdvertisementsLikeCarousel ? 1 : 0}},{__component:featured_products,hideDescription:true,ng-if:$ctrl.template !PageGuide},{__component:article_plates,type:list-compact,start:0,number:6,showTitle:true,articleType:saved,title:Saved news,ng-if:$ctrl.settings.cookiesModel.isAuthenticated()},{__component:article_plates,type:list-compact,start:1,number:6,showTitle:true,articleType:shared,title:Popular on social,params:{days:5}},{__component:article_plates,type:list-compact,start:0,number:7,showTitle:true,articleType:featured-content,title:Sponsored Articles},{__component:subscribe_user,display:true},{__component:personalize_items,number:6,entityTypes:7,8,9,10,openAsLinks:true,title:Featured Sources,ng-show:$ctrl.template.indexOf(Guide) \u003c 0},{__component:twitter,#text:Industry Tweets},{__component:article_plates,type:list-compact,start:0,number:6,showTitle:true,articleType:organizer-news,title:Organizer news},{__component:newsletter_archive,count:5},BuyersGuideMain:{__component:article_plates,type:list-compact,start:0,number:10,showTitle:true,articleType:recent,title:Industry News,options:{col:2}},{__component:site-banner},{__component:advertisement,options:{code:B-A,order:0,number:5}},{__component:left-bg-data},{__component:bg-right-section},{__component:advertisement,options:{code:B-D,order:0,number:5}},{__component:site-search,options:{columns:1,col:1}},{__component:site-categories,options:{columns:2,col:1}},RightSection1Layout1:{__component:partnered-with},{__component:subscribe_user,display:true,options:{trending:true}},{__component:social-links},{__component:advertisement,options:{code:N-S,number:5,displayType:1}},{__component:advertisement,options:{code:N-R,number:5,displayType:1}},{__component:newsletter_archive,count:5},SiteHeader1:{__component:site-banner},{__component:navbar,options:{left:{html:\u003cspan idnavbar-branded-content\u003e\u003c/span\u003e,name:BRANDED CONTENT,href:/branded-content,target:_self},{html:\u003cspan idnavbar-press-releases\u003e\u003c/span\u003e,name:PRESS RELEASES,href:/press-releases,target:_self},{html:\u003cspan idnavbar-webinars\u003e\u003c/span\u003e,name:WEBINARS,href:/webinars,target:_self},{html:\u003cspan idnavbar-contact\u003e\u003c/span\u003e,name:CONTACT,href:mailto:,target:_self},{html:\u003cspan idnavbar-advertise\u003e\u003c/span\u003e,name:ADVERTISE,href:/advertise,target:_self},{html:\u003cspan idnavbar-search\u003e\u003c/span\u003e,name:SEARCH,href:/search,target:_self},right:}},SiteMain1:{__component:feed,options:{trending:true}},{__component:right-panel},SiteFooter1:{__component:site-footer,options:{trending:true,fullWidth:true,type:Lauout1}}},themeData:{name:INS1,headerSelector:div#top-header, header#main-header,footerSelector:div.et_pb_section_19,footer#main-footer,headerHtml:\u003cdiv id\ins1-top-header\\u003e\n\t\t\t\u003cdiv class\ins1-container ins1-clearfix\\u003e\n\n\t\t\t\n\t\t\t\t\u003cdiv id\ins1-et-info\\u003e\n\t\t\t\t\t\t\t\t\t\u003cspan id\ins1-et-info-phone\\u003e781-440-9408\u003c/span\u003e\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\u003ca href\mailto:ins@ins1.org\\u003e\u003cspan id\ins1-et-info-email\\u003eins@ins1.org\u003c/span\u003e\u003c/a\u003e\n\t\t\t\t\n\t\t\t\t\t\t\t\t\u003c/div\u003e \u003c!-- #et-info --\u003e\n\n\t\t\t\n\t\t\t\t\u003cdiv id\ins1-et-secondary-menu\\u003e\n\t\t\t\t\t\t\t\t\u003c/div\u003e \u003c!-- #et-secondary-menu --\u003e\n\n\t\t\t\u003c/div\u003e \u003c!-- .container --\u003e\n\t\t\u003c/div\u003e\u003cheader id\ins1-main-header\ data-height-onload\66\\u003e\n\t\t\t\u003cdiv class\ins1-container ins1-clearfix ins1-et_menu_container\\u003e\n\t\t\t\t\t\t\t\u003cdiv class\ins1-logo_container\\u003e\n\t\t\t\t\t\u003cspan class\ins1-logo_helper\\u003e\u003c/span\u003e\n\t\t\t\t\t\u003ca href\https://www.ins1.org/\\u003e\n\t\t\t\t\t\t\u003cimg src\https://www.ins1.org/wp-content/uploads/2018/03/INS_Logo_Solo_Blue.png\ alt\INS\ id\ins1-logo\ data-height-percentage\54\ data-actual-width\785\ data-actual-height\338.641\\u003e\n\t\t\t\t\t\u003c/a\u003e\n\t\t\t\t\u003c/div\u003e\n\t\t\t\t\t\t\t\u003cdiv id\ins1-et-top-navigation\ data-height\66\ data-fixed-height\40\\u003e\n\t\t\t\t\t\t\t\t\t\t\t\u003cnav id\ins1-top-menu-nav\\u003e\n\t\t\t\t\t\t\u003cul id\ins1-top-menu\ class\ins1-nav\\u003e\u003cli id\ins1-menu-item-202\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-202\\u003e\u003ca href\https://www.ins1.org/about-us/\\u003eAbout\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-2500\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-2500\\u003e\u003ca href\https://www.ins1.org/about-us/\\u003eINS Mission \u0026amp; Values\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-4116\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-4116\\u003e\u003ca href\https://www.ins1.org/about-us/ins-diversity-equity-and-inclusion/\\u003eINS Diversity, Equity and Inclusion\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-204\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-204\\u003e\u003ca href\https://www.ins1.org/about-us/ins-team/\\u003eINS Team\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-570\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-570\\u003e\u003ca href\https://www.ins1.org/about-us/ins-board-of-directors/\\u003eINS Board of Directors\u003c/a\u003e\n\t\u003cul class\ins1-sub-menu\\u003e\n\t\t\u003cli id\ins1-menu-item-4371\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-4371\\u003e\u003ca href\https://www.ins1.org/about-us/ins-board-of-directors/ins-board-of-directors-nominations/\\u003eINS Board of Directors Nominations\u003c/a\u003e\u003c/li\u003e\n\t\u003c/ul\u003e\n\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-207\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-207\\u003e\u003ca href\https://www.ins1.org/about-us/iv-nurse-day/\\u003eIV Nurse Day\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-203\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-203\\u003e\u003ca href\https://www.ins1.org/about-us/gardner-foundation/\\u003eGardner Foundation\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-2888\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-2888\\u003e\u003ca href\https://www.ins1.org/ins-partners/\\u003eINS Partners\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-228\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-228\\u003e\u003ca href\https://www.ins1.org/about-us/news-events/\\u003eNews \u0026amp; Events\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-2363\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-has-children ins1-menu-item-2363\\u003e\u003ca href\https://fontevacustomer-1614e2ff498.force.com/ins/joinapi__login?ida2E3m000001SJx5EAG\u0026amp;order1\\u003eMembership\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-2796\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-2796\\u003e\u003ca href\https://www.ins1.org/join/\\u003eJoin\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-1666\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-1666\\u003e\u003ca href\https://www.ins1.org/membership/awards-and-recognition/\\u003eAwards and Recognition\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-4083\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-4083\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.ins1.org/wp-content/uploads/2021/02/Benefits-of-INS-Membership_2021.pdf\\u003eBenefits of INS Membership (pdf)\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-220\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-220\\u003e\u003ca href\https://www.ins1.org/membership/corporate-sponsorship/\\u003eCorporate Sponsorship\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-221\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-221\\u003e\u003ca href\https://www.ins1.org/membership/international-affiliates/\\u003eInternational Affiliates\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-3454\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-3454\\u003e\u003ca href\https://www.ins1.org/membership/ins-chapters/\\u003eINS Chapters\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-230\ class\ins1-external-link ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-has-children ins1-menu-item-230\\u003e\u003ca title\LEARNING CENTER\ target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/\\u003eLEARNING CENTER\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-2697\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-2697\\u003e\u003ca href\https://www.learningcenter.ins1.org/p/FIT\\u003eFundamentals\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-231\ class\ins1-external-link ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-231\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/webinars\\u003eWebinars\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-244\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-244\\u003e\u003ca href\https://www.learningcenter.ins1.org/conference-learning\\u003eConference Learning\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-232\ class\ins1-external-link ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-232\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/anytime-learning\\u003eAnytime Learning\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-234\ class\ins1-external-link ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-234\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/position-papers\\u003ePosition Papers\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-235\ class\ins1-external-link ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-235\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/podcasts\\u003ePodcasts\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-239\ class\ins1-external-link ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-239\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/virtual-infusion-education\\u003eVirtual Infusion Education\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-1597\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-1597\\u003e\u003ca href\https://www.learningcenter.ins1.org/recertify\\u003eCRNI® Recertification Approved\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-208\ class\ins1-mega-menu ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-208 ins1-mega-menu-parent ins1-mega-menu-parent-3\\u003e\u003ca href\https://www.ins1.org/crni-certification/\\u003eCertification\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-295\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-295\\u003e\u003ca href\https://www.ins1.org/crni-certification/about-incc/\\u003eAbout INCC\u003c/a\u003e\n\t\u003cul class\ins1-sub-menu\\u003e\n\t\t\u003cli id\ins1-menu-item-2280\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-2280\\u003e\u003ca href\https://www.ins1.org/crni-certification/about-incc/\\u003eINCC Mission and Values\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-304\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-304\\u003e\u003ca href\https://www.ins1.org/crni-certification/about-incc/board-of-directors/\\u003eBoard of Directors\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-1828\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-1828\\u003e\u003ca href\https://www.ins1.org/crni-certification/information/general-information/\\u003eGeneral Information\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-305\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-305\\u003e\u003ca href\https://www.ins1.org/crni-certification/about-incc/verify-a-crni/\\u003eVerify a CRNI®\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-3498\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-3498\\u003e\u003ca href\https://www.ins1.org/crni-certification/information/frequently-asked-questions/\\u003eFrequently Asked Questions\u003c/a\u003e\u003c/li\u003e\n\t\u003c/ul\u003e\n\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-1778\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-1778\\u003e\u003ca href\https://www.ins1.org/crni-certification/\\u003eExam\u003c/a\u003e\n\t\u003cul class\ins1-sub-menu\\u003e\n\t\t\u003cli id\ins1-menu-item-290\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-290\\u003e\u003ca href\https://www.ins1.org/crni-certification/exam/exam-basics/\\u003eExam Basics\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-1776\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-1776\\u003e\u003ca href\https://www.ins1.org/crni-certification/exam/\\u003eExam Content\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-289\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-289\\u003e\u003ca href\https://www.ins1.org/crni-certification/exam/register/\\u003eRegister\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-281\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-281\\u003e\u003ca href\https://www.ins1.org/crni-certification/information/study-information/\\u003eStudy Information\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-1013\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-1013\\u003e\u003ca href\https://ins.benchprep.com/learn-more\\u003eCRNI® Academy\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-280\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-280\\u003e\u003ca href\https://www.ins1.org/crni-resources/\\u003eCRNI® Resource Information\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-288\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-288\\u003e\u003ca href\https://www.ins1.org/crni-certification/exam/exam-results/\\u003eExam Results\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-282\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-282\\u003e\u003ca href\https://www.ins1.org/crni-certification/about-incc/crni-digital-badge/\\u003eCRNI® Digital Badge\u003c/a\u003e\u003c/li\u003e\n\t\u003c/ul\u003e\n\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-292\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-292\\u003e\u003ca href\https://www.ins1.org/crni-certification/recertification/\\u003eRecertification\u003c/a\u003e\n\t\u003cul class\ins1-sub-menu\\u003e\n\t\t\u003cli id\ins1-menu-item-287\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-287\\u003e\u003ca href\https://www.ins1.org/crni-certification/recertification/recertification-by-exam/\\u003eRecertification by Exam\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-286\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-286\\u003e\u003ca href\https://www.ins1.org/crni-certification/recertification/recertification-by-ce/\\u003eRecertification by CE\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-285\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-285\\u003e\u003ca href\https://www.ins1.org/crni-certification/recertification/recertification-by-ce/recertification-ru-options/\\u003eRecertification RU Options\u003c/a\u003e\u003c/li\u003e\n\t\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-4845\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-4845\\u003e\u003ca href\https://www.ins1.org/educational-programming/\\u003eEducational Programming\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-3054\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-3054\\u003e\u003ca href\https://www.ins1.org/about-us/fit/\\u003eINS FIT Program\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-1854\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-1854\\u003e\u003ca target\_blank\ rel\noopener\ href\https://fontevacustomer-1614e2ff498.force.com/ins/s/lt-event?ida1U3m00000Pj09BEAR\\u003eAnnual Meeting\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-4847\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-4847\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/virtual-infusion-education\\u003eVirtual Infusion Education\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-4848\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-4848\\u003e\u003ca target\_blank\ rel\noopener\ href\https://fontevacustomer-1614e2ff498.force.com/ins/s/speaking-opportunities\\u003eSpeaking Opportunities\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-1030\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-1030\\u003e\u003ca href\https://www.ins1.org/educational-programming/exhibit/\\u003eExhibit\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-4846\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-4846\\u003e\u003ca href\https://www.ins1.org/educational-programming/media-and-promotional-guide/\\u003eMedia \u0026amp; Promotional Guide\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-225\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-225\\u003e\u003ca href\https://www.ins1.org/publications/\\u003ePublications\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-226\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-226\\u003e\u003ca href\https://www.ins1.org/publications/insider/\\u003eINSider\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-5261\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-5261\\u003e\u003ca href\https://www.ins1.org/publications/infusion-therapy-standards-of-practice/\\u003eInfusion Therapy Standards of Practice\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-227\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-227\\u003e\u003ca href\https://www.ins1.org/publications/journal-of-infusion-nursing/\\u003eJournal of Infusion Nursing\u003c/a\u003e\n\t\u003cul class\ins1-sub-menu\\u003e\n\t\t\u003cli id\ins1-menu-item-1566\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-1566\\u003e\u003ca href\https://www.ins1.org/publications/journal-of-infusion-nursing/submit-a-manuscript/\\u003eSubmit a Manuscript\u003c/a\u003e\u003c/li\u003e\n\t\u003c/ul\u003e\n\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-5034\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-5034\\u003e\u003ca href\https://www.ins1.org/policies-and-procedures-for-infusion-therapy/\\u003ePolicies and Procedures for Infusion Therapy\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-2220\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-has-children ins1-menu-item-2220\\u003e\u003ca title\Store\ target\_blank\ rel\noopener\ href\https://fontevacustomer-1614e2ff498.force.com/ins/s/store\\u003eStore\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-2396\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-2396\\u003e\u003ca href\http://ins.tizrapublisher.com/\\u003eDigital Bookstore\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-2221\ class\ins1-nav-btn ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-2221\\u003e\u003ca title\Member Login\ target\_blank\ rel\noopener\ href\https://fontevacustomer-1614e2ff498.force.com/ins/s/login/\\u003eLogin\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\t\t\t\t\t\t\u003c/nav\u003e\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\u003cdiv id\ins1-et_top_search\\u003e\n\t\t\t\t\t\t\u003cspan id\ins1-et_search_icon\\u003e\u003c/span\u003e\n\t\t\t\t\t\u003c/div\u003e\n\t\t\t\t\t\n\t\t\t\t\t\u003cdiv id\ins1-et_mobile_nav_menu\\u003e\n\t\t\t\t\u003cdiv class\ins1-mobile_nav ins1-closed\\u003e\n\t\t\t\t\t\u003cspan class\ins1-select_page\\u003eSelect Page\u003c/span\u003e\n\t\t\t\t\t\u003cspan class\ins1-mobile_menu_bar ins1-mobile_menu_bar_toggle\\u003e\u003c/span\u003e\n\t\t\t\t\u003cul id\ins1-mobile_menu\ class\ins1-et_mobile_menu\\u003e\u003cli id\ins1-menu-item-202\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-202 ins1-et_first_mobile_item\\u003e\u003ca href\https://www.ins1.org/about-us/\\u003eAbout\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-2500\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-2500\\u003e\u003ca href\https://www.ins1.org/about-us/\\u003eINS Mission \u0026amp; Values\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-4116\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-4116\\u003e\u003ca href\https://www.ins1.org/about-us/ins-diversity-equity-and-inclusion/\\u003eINS Diversity, Equity and Inclusion\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-204\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-204\\u003e\u003ca href\https://www.ins1.org/about-us/ins-team/\\u003eINS Team\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-570\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-570\\u003e\u003ca href\https://www.ins1.org/about-us/ins-board-of-directors/\\u003eINS Board of Directors\u003c/a\u003e\n\t\u003cul class\ins1-sub-menu\\u003e\n\t\t\u003cli id\ins1-menu-item-4371\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-4371\\u003e\u003ca href\https://www.ins1.org/about-us/ins-board-of-directors/ins-board-of-directors-nominations/\\u003eINS Board of Directors Nominations\u003c/a\u003e\u003c/li\u003e\n\t\u003c/ul\u003e\n\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-207\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-207\\u003e\u003ca href\https://www.ins1.org/about-us/iv-nurse-day/\\u003eIV Nurse Day\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-203\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-203\\u003e\u003ca href\https://www.ins1.org/about-us/gardner-foundation/\\u003eGardner Foundation\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-2888\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-2888\\u003e\u003ca href\https://www.ins1.org/ins-partners/\\u003eINS Partners\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-228\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-228\\u003e\u003ca href\https://www.ins1.org/about-us/news-events/\\u003eNews \u0026amp; Events\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-2363\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-has-children ins1-menu-item-2363\\u003e\u003ca href\https://fontevacustomer-1614e2ff498.force.com/ins/joinapi__login?ida2E3m000001SJx5EAG\u0026amp;order1\\u003eMembership\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-2796\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-2796\\u003e\u003ca href\https://www.ins1.org/join/\\u003eJoin\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-1666\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-1666\\u003e\u003ca href\https://www.ins1.org/membership/awards-and-recognition/\\u003eAwards and Recognition\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-4083\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-4083\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.ins1.org/wp-content/uploads/2021/02/Benefits-of-INS-Membership_2021.pdf\\u003eBenefits of INS Membership (pdf)\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-220\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-220\\u003e\u003ca href\https://www.ins1.org/membership/corporate-sponsorship/\\u003eCorporate Sponsorship\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-221\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-221\\u003e\u003ca href\https://www.ins1.org/membership/international-affiliates/\\u003eInternational Affiliates\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-3454\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-3454\\u003e\u003ca href\https://www.ins1.org/membership/ins-chapters/\\u003eINS Chapters\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-230\ class\ins1-external-link ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-has-children ins1-menu-item-230\\u003e\u003ca title\LEARNING CENTER\ target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/\\u003eLEARNING CENTER\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-2697\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-2697\\u003e\u003ca href\https://www.learningcenter.ins1.org/p/FIT\\u003eFundamentals\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-231\ class\ins1-external-link ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-231\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/webinars\\u003eWebinars\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-244\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-244\\u003e\u003ca href\https://www.learningcenter.ins1.org/conference-learning\\u003eConference Learning\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-232\ class\ins1-external-link ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-232\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/anytime-learning\\u003eAnytime Learning\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-234\ class\ins1-external-link ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-234\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/position-papers\\u003ePosition Papers\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-235\ class\ins1-external-link ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-235\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/podcasts\\u003ePodcasts\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-239\ class\ins1-external-link ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-239\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/virtual-infusion-education\\u003eVirtual Infusion Education\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-1597\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-1597\\u003e\u003ca href\https://www.learningcenter.ins1.org/recertify\\u003eCRNI® Recertification Approved\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-208\ class\ins1-mega-menu ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-208 ins1-mega-menu-parent ins1-mega-menu-parent-3\\u003e\u003ca href\https://www.ins1.org/crni-certification/\\u003eCertification\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-295\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-295\\u003e\u003ca href\https://www.ins1.org/crni-certification/about-incc/\\u003eAbout INCC\u003c/a\u003e\n\t\u003cul class\ins1-sub-menu\\u003e\n\t\t\u003cli id\ins1-menu-item-2280\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-2280\\u003e\u003ca href\https://www.ins1.org/crni-certification/about-incc/\\u003eINCC Mission and Values\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-304\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-304\\u003e\u003ca href\https://www.ins1.org/crni-certification/about-incc/board-of-directors/\\u003eBoard of Directors\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-1828\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-1828\\u003e\u003ca href\https://www.ins1.org/crni-certification/information/general-information/\\u003eGeneral Information\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-305\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-305\\u003e\u003ca href\https://www.ins1.org/crni-certification/about-incc/verify-a-crni/\\u003eVerify a CRNI®\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-3498\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-3498\\u003e\u003ca href\https://www.ins1.org/crni-certification/information/frequently-asked-questions/\\u003eFrequently Asked Questions\u003c/a\u003e\u003c/li\u003e\n\t\u003c/ul\u003e\n\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-1778\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-1778\\u003e\u003ca href\https://www.ins1.org/crni-certification/\\u003eExam\u003c/a\u003e\n\t\u003cul class\ins1-sub-menu\\u003e\n\t\t\u003cli id\ins1-menu-item-290\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-290\\u003e\u003ca href\https://www.ins1.org/crni-certification/exam/exam-basics/\\u003eExam Basics\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-1776\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-1776\\u003e\u003ca href\https://www.ins1.org/crni-certification/exam/\\u003eExam Content\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-289\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-289\\u003e\u003ca href\https://www.ins1.org/crni-certification/exam/register/\\u003eRegister\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-281\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-281\\u003e\u003ca href\https://www.ins1.org/crni-certification/information/study-information/\\u003eStudy Information\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-1013\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-1013\\u003e\u003ca href\https://ins.benchprep.com/learn-more\\u003eCRNI® Academy\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-280\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-280\\u003e\u003ca href\https://www.ins1.org/crni-resources/\\u003eCRNI® Resource Information\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-288\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-288\\u003e\u003ca href\https://www.ins1.org/crni-certification/exam/exam-results/\\u003eExam Results\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-282\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-282\\u003e\u003ca href\https://www.ins1.org/crni-certification/about-incc/crni-digital-badge/\\u003eCRNI® Digital Badge\u003c/a\u003e\u003c/li\u003e\n\t\u003c/ul\u003e\n\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-292\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-292\\u003e\u003ca href\https://www.ins1.org/crni-certification/recertification/\\u003eRecertification\u003c/a\u003e\n\t\u003cul class\ins1-sub-menu\\u003e\n\t\t\u003cli id\ins1-menu-item-287\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-287\\u003e\u003ca href\https://www.ins1.org/crni-certification/recertification/recertification-by-exam/\\u003eRecertification by Exam\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-286\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-286\\u003e\u003ca href\https://www.ins1.org/crni-certification/recertification/recertification-by-ce/\\u003eRecertification by CE\u003c/a\u003e\u003c/li\u003e\n\t\t\u003cli id\ins1-menu-item-285\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-285\\u003e\u003ca href\https://www.ins1.org/crni-certification/recertification/recertification-by-ce/recertification-ru-options/\\u003eRecertification RU Options\u003c/a\u003e\u003c/li\u003e\n\t\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-4845\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-4845\\u003e\u003ca href\https://www.ins1.org/educational-programming/\\u003eEducational Programming\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-3054\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-3054\\u003e\u003ca href\https://www.ins1.org/about-us/fit/\\u003eINS FIT Program\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-1854\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-1854\\u003e\u003ca target\_blank\ rel\noopener\ href\https://fontevacustomer-1614e2ff498.force.com/ins/s/lt-event?ida1U3m00000Pj09BEAR\\u003eAnnual Meeting\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-4847\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-4847\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/virtual-infusion-education\\u003eVirtual Infusion Education\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-4848\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-4848\\u003e\u003ca target\_blank\ rel\noopener\ href\https://fontevacustomer-1614e2ff498.force.com/ins/s/speaking-opportunities\\u003eSpeaking Opportunities\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-1030\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-1030\\u003e\u003ca href\https://www.ins1.org/educational-programming/exhibit/\\u003eExhibit\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-4846\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-4846\\u003e\u003ca href\https://www.ins1.org/educational-programming/media-and-promotional-guide/\\u003eMedia \u0026amp; Promotional Guide\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-225\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-225\\u003e\u003ca href\https://www.ins1.org/publications/\\u003ePublications\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-226\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-226\\u003e\u003ca href\https://www.ins1.org/publications/insider/\\u003eINSider\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-5261\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-5261\\u003e\u003ca href\https://www.ins1.org/publications/infusion-therapy-standards-of-practice/\\u003eInfusion Therapy Standards of Practice\u003c/a\u003e\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-227\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-has-children ins1-menu-item-227\\u003e\u003ca href\https://www.ins1.org/publications/journal-of-infusion-nursing/\\u003eJournal of Infusion Nursing\u003c/a\u003e\n\t\u003cul class\ins1-sub-menu\\u003e\n\t\t\u003cli id\ins1-menu-item-1566\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-1566\\u003e\u003ca href\https://www.ins1.org/publications/journal-of-infusion-nursing/submit-a-manuscript/\\u003eSubmit a Manuscript\u003c/a\u003e\u003c/li\u003e\n\t\u003c/ul\u003e\n\u003c/li\u003e\n\t\u003cli id\ins1-menu-item-5034\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-5034\\u003e\u003ca href\https://www.ins1.org/policies-and-procedures-for-infusion-therapy/\\u003ePolicies and Procedures for Infusion Therapy\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-2220\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-has-children ins1-menu-item-2220\\u003e\u003ca title\Store\ target\_blank\ rel\noopener\ href\https://fontevacustomer-1614e2ff498.force.com/ins/s/store\\u003eStore\u003c/a\u003e\n\u003cul class\ins1-sub-menu\\u003e\n\t\u003cli id\ins1-menu-item-2396\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-2396\\u003e\u003ca href\http://ins.tizrapublisher.com/\\u003eDigital Bookstore\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli id\ins1-menu-item-2221\ class\ins1-nav-btn ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-2221\\u003e\u003ca title\Member Login\ target\_blank\ rel\noopener\ href\https://fontevacustomer-1614e2ff498.force.com/ins/s/login/\\u003eLogin\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\u003c/div\u003e\n\t\t\t\u003c/div\u003e\t\t\t\t\u003c/div\u003e \u003c!-- #et-top-navigation --\u003e\n\t\t\t\u003c/div\u003e \u003c!-- .container --\u003e\n\t\t\t\u003cdiv class\ins1-et_search_outer\\u003e\n\t\t\t\t\u003cdiv class\ins1-container ins1-et_search_form_container\\u003e\n\t\t\t\t\t\u003cform role\search\ method\get\ class\ins1-et-search-form\ action\https://www.ins1.org/\\u003e\n\t\t\t\t\t\u003cinput type\search\ class\ins1-et-search-field\ placeholder\Search …\ value\\ name\s\ title\Search for:\\u003e\t\t\t\t\t\u003c/form\u003e\n\t\t\t\t\t\u003cspan class\ins1-et_close_search_field\\u003e\u003c/span\u003e\n\t\t\t\t\u003c/div\u003e\n\t\t\t\u003c/div\u003e\n\t\t\u003c/header\u003e,footerHtml:\u003cdiv class\ins1-et_pb_section ins1-et_pb_section_19 ins1-et_pb_with_background ins1-et_section_regular\\u003e\n\n\n\n\n \u003cdiv class\ins1-et_pb_row ins1-et_pb_row_17 ins1-et_pb_row_fullwidth\\u003e\n \u003cdiv class\ins1-et_pb_column ins1-et_pb_column_1_4 ins1-et_pb_column_23 ins1-et_pb_css_mix_blend_mode_passthrough\\u003e\n\n\n \u003cdiv class\ins1-et_pb_module ins1-et_pb_text ins1-et_pb_text_22 ins1-et_clickable ins1-et_pb_text_align_left ins1-et_pb_bg_layout_light\\u003e\n\n\n \u003cdiv class\ins1-et_pb_text_inner\\u003e\n \u003ch4\u003eAbout INS\u003c/h4\u003e\n \u003cp\u003eThe Infusion Nurses Society (INS) is an international nonprofit organization representing infusion nurses and other clinicians\u0026nbsp; who are engaged in the specialty practice of infusion therapy.\u003cbr\u003e \u003ca href\https://fontevacustomer-1614e2ff498.force.com/ins/s/login/\\n target\_blank\ rel\noopener noreferrer\\u003eJoin Today \u0026gt;\u003c/a\u003e\u003c/p\u003e\n \u003c/div\u003e\n \u003c/div\u003e\n \u003c!-- .et_pb_text --\u003e\n \u003cul class\ins1-et_pb_module ins1-et_pb_social_media_follow ins1-et_pb_social_media_follow_0 ins1-footer-follow-icons ins1-clearfix ins1-et_pb_bg_layout_light\\u003e\n\n\n \u003cli class\ins1-et_pb_social_media_follow_network_0 ins1-et_pb_social_icon ins1-et_pb_social_network_link ins1-et-social-linkedin ins1-et_pb_social_media_follow_network_0\\u003e\u003ca href\https://www.linkedin.com/company/infusion-nurses-society\ class\ins1-icon ins1-et_pb_with_border\ title\Follow on LinkedIn\ target\_blank\\u003e\u003cspan class\ins1-et_pb_social_media_follow_network_name\ aria-hidden\true\\u003eFollow\u003c/span\u003e\u003c/a\u003e\u003c/li\u003e\n \u003cli\n class\ins1-et_pb_social_media_follow_network_1 ins1-et_pb_social_icon ins1-et_pb_social_network_link ins1-et-social-facebook ins1-et_pb_social_media_follow_network_1\\u003e\u003ca href\https://www.facebook.com/InfusionNursesSociety/\ class\ins1-icon ins1-et_pb_with_border\ title\Follow on Facebook\ target\_blank\\u003e\u003cspan class\ins1-et_pb_social_media_follow_network_name\ aria-hidden\true\\u003eFollow\u003c/span\u003e\u003c/a\u003e\u003c/li\u003e\n \u003cli\n class\ins1-et_pb_social_media_follow_network_2 ins1-et_pb_social_icon ins1-et_pb_social_network_link ins1-et-social-twitter ins1-et_pb_social_media_follow_network_2\\u003e\u003ca href\https://twitter.com/ins1org\ class\ins1-icon ins1-et_pb_with_border\ title\Follow on Twitter\ target\_blank\\u003e\u003cspan class\ins1-et_pb_social_media_follow_network_name\ aria-hidden\true\\u003eFollow\u003c/span\u003e\u003c/a\u003e\u003c/li\u003e\n \u003cli class\ins1-et_pb_social_media_follow_network_3 ins1-et_pb_social_icon ins1-et_pb_social_network_link ins1-et-social-instagram ins1-et_pb_social_media_follow_network_3\\u003e\u003ca href\https://www.instagram.com/infusionnursessociety/\ class\ins1-icon ins1-et_pb_with_border\ title\Follow on Instagram\ target\_blank\\u003e\u003cspan class\ins1-et_pb_social_media_follow_network_name\ aria-hidden\true\\u003eFollow\u003c/span\u003e\u003c/a\u003e\u003c/li\u003e\n \u003c/ul\u003e\n \u003c!-- .et_pb_counters --\u003e\n \u003c/div\u003e\n \u003c!-- .et_pb_column --\u003e\n \u003cdiv class\ins1-et_pb_column ins1-et_pb_column_1_4 ins1-et_pb_column_24 ins1-et_pb_css_mix_blend_mode_passthrough ins1-et_pb_column_empty\\u003e\n\n\n\n \u003c/div\u003e\n \u003c!-- .et_pb_column --\u003e\n \u003cdiv class\ins1-et_pb_column ins1-et_pb_column_1_4 ins1-et_pb_column_25 ins1-et_pb_css_mix_blend_mode_passthrough\\u003e\n\n\n \u003cdiv class\ins1-et_pb_module ins1-et_pb_text ins1-et_pb_text_23 ins1-et_pb_text_align_left ins1-et_pb_bg_layout_light\\u003e\n\n\n \u003cdiv class\ins1-et_pb_text_inner\\u003e\n \u003ch4\u003eContact Us\u003c/h4\u003e\n \u003cp\u003eOne Edgewater Drive\u003cbr\u003e Suite 209\u003cbr\u003e Norwood, MA 02062\u003c/p\u003e\n \u003cp\u003e\u003cspan\u003ePhone: (781) 440-9408\u003c/span\u003e\u003cbr\u003e\u003cspan\u003e Fax: (781) 440-9409\u003c/span\u003e\u003cbr\u003e\u003cspan\u003e Email: \u003ca href\mailto:ins@ins1.org\ target\_blank\ rel\noopener noreferrer\\u003eins@ins1.org\u003c/a\u003e\u003c/span\u003e\u003c/p\u003e\n \u003c/div\u003e\n \u003c/div\u003e\n \u003c!-- .et_pb_text --\u003e\n \u003c/div\u003e\n \u003c!-- .et_pb_column --\u003e\n \u003cdiv class\ins1-et_pb_column ins1-et_pb_column_1_4 ins1-et_pb_column_26 ins1-sponsored-by ins1-et_pb_css_mix_blend_mode_passthrough ins1-et-last-child\\u003e\n\n\n \u003cdiv class\ins1-et_pb_module ins1-et_pb_text ins1-et_pb_text_24 ins1-et_pb_text_align_left ins1-et_pb_bg_layout_light\\u003e\n\n\n \u003cdiv class\ins1-et_pb_text_inner\\u003e\n \u003ch4\u003eSponsored By\u003c/h4\u003e\n \u003c/div\u003e\n \u003c/div\u003e\n \u003c!-- .et_pb_text --\u003e\n \u003cdiv id\ins1-site-sponsor\ class\ins1-et_pb_module ins1-et_pb_image ins1-et_pb_image_9\\u003e\n\n\n \u003ca href\https://www.bbraunusa.com/en.html\ target\_blank\\u003e\u003cspan class\ins1-et_pb_image_wrap\\u003e\u003cimg src\https://162.144.84.44/~insdemoc/wp-content/uploads/2019/06/BBRAUN.png\ alt\\ title\\ height\auto\ width\auto\ srcset\https://www.ins1.org/wp-content/uploads/2019/06/BBRAUN.png 1383w, https://www.ins1.org/wp-content/uploads/2019/06/BBRAUN-300x74.png 300w, https://www.ins1.org/wp-content/uploads/2019/06/BBRAUN-768x189.png 768w, https://www.ins1.org/wp-content/uploads/2019/06/BBRAUN-1024x252.png 1024w, https://www.ins1.org/wp-content/uploads/2019/06/BBRAUN-610x150.png 610w, https://www.ins1.org/wp-content/uploads/2019/06/BBRAUN-1080x266.png 1080w\ sizes\(max-width: 1383px) 100vw, 1383px\ class\ins1-wp-image-1670\\u003e\u003c/span\u003e\u003c/a\u003e\n \u003c/div\u003e\n \u003c/div\u003e\n \u003c!-- .et_pb_column --\u003e\n\n\n \u003c/div\u003e\n \u003c!-- .et_pb_row --\u003e\n\n\n\u003c/div\u003e\n\u003cfooter id\ins1-main-footer\\u003e\n\n\n\n \u003cdiv id\ins1-et-footer-nav\\u003e\n \u003cdiv class\ins1-container\\u003e\n \u003cul id\ins1-menu-footer-menu\ class\ins1-bottom-nav\\u003e\n \u003cli id\ins1-menu-item-2238\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-home ins1-current-menu-item ins1-page_item ins1-page-item-48 ins1-current_page_item ins1-menu-item-2238\\u003e\u003ca href\https://www.ins1.org/\ aria-current\page\\u003eHome\u003c/a\u003e\u003c/li\u003e\n \u003cli id\ins1-menu-item-2239\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-2239\\u003e\u003ca href\https://www.ins1.org/about-us/\\u003eAbout\u003c/a\u003e\u003c/li\u003e\n \u003cli id\ins1-menu-item-2501\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-2501\\u003e\u003ca target\_blank\ rel\noopener\ href\https://fontevacustomer-1614e2ff498.force.com/ins/s/login/\\u003eMembership\u003c/a\u003e\u003c/li\u003e\n \u003cli id\ins1-menu-item-2482\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-2482\\u003e\u003ca href\http://careercenter.ins1.org/\\u003eCareer Center\u003c/a\u003e\u003c/li\u003e\n \u003cli id\ins1-menu-item-2245\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-2245\\u003e\u003ca target\_blank\ rel\noopener\ href\https://www.learningcenter.ins1.org/\\u003eLEARNING CENTER\u003c/a\u003e\u003c/li\u003e\n \u003cli id\ins1-menu-item-2240\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-2240\\u003e\u003ca href\https://www.ins1.org/crni-certification/\\u003eCertification\u003c/a\u003e\u003c/li\u003e\n \u003cli id\ins1-menu-item-4849\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-4849\\u003e\u003ca href\https://www.ins1.org/educational-programming/\\u003eEducational Programming\u003c/a\u003e\u003c/li\u003e\n \u003cli id\ins1-menu-item-2244\ class\ins1-menu-item ins1-menu-item-type-post_type ins1-menu-item-object-page ins1-menu-item-2244\\u003e\u003ca href\https://www.ins1.org/publications/\\u003ePublications\u003c/a\u003e\u003c/li\u003e\n \u003cli id\ins1-menu-item-2246\ class\ins1-menu-item ins1-menu-item-type-custom ins1-menu-item-object-custom ins1-menu-item-2246\\u003e\u003ca target\_blank\ rel\noopener\ href\https://fontevacustomer-1614e2ff498.force.com/ins/s/store\\u003eStore\u003c/a\u003e\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/div\u003e\n \u003c/div\u003e\n \u003c!-- #et-footer-nav --\u003e\n\n\n \u003cdiv id\ins1-footer-bottom\\u003e\n \u003cdiv class\ins1-container ins1-clearfix\\u003e\n \u003cp id\ins1-footer-info\\u003eCopyright © \u003ca href\https://www.ins1.org/\\u003e2023 www.ins1.org\u003c/a\u003e\u003c/p\u003e\n \u003c/div\u003e\n \u003c!-- .container --\u003e\n \u003c/div\u003e\n \u003clink rel\stylesheet\ href\https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.2.0/css/font-awesome.css\ integrity\sha512-YTuMx+CIxXa1l+j5aDPm98KFbVcYFNhlr2Auha3pwjHCF1lLbY9/ITQQlsUzdM1scW45kHC5KNib4mNa1IFvJg\ crossorigin\anonymous\ referrerpolicy\no-referrer\\n /\u003e\n\u003c/footer\u003e,cssStyles:@import url(https://fonts.googleapis.com/css2?familyLato:wght@300;400;700;900\u0026familyMada:wght@300;400;500;600;700\u0026displayswap);\r\n\r\n\r\n#ins1-et_top_search,\r\n.ins1-et_search_outer,\r\n#ins1-et_mobile_nav_menu{\r\n display: none !important;\r\n}\r\n\r\n.ins1-nav-btn {\r\n background-color: #0f4d81;\r\n color: #fff;\r\n padding: 0!important;\r\n}\r\n\r\n.ins1-nav-btn a {\r\n color: #fff!important;\r\n padding: 10px 5%;\r\n}\r\n\r\n@media (min-width: 980px) {\r\n .ins1-nav-btn a {\r\n padding: 15px 15px 15px 35px!important;\r\n }\r\n .ins1-nav-btn a:before {\r\n content: \\\f023\;\r\n color: #fff;\r\n font: normal normal normal 16px/1 FontAwesome;\r\n position: absolute;\r\n left: 12px;\r\n }\r\n}\r\n\r\n#ins1-main-header {\r\n line-height: 23px;\r\n font-weight: 500;\r\n top: 0;\r\n background-color: #fff;\r\n width: 100%;\r\n box-shadow: 0 1px 0 rgba(0,0,0,.1);\r\n position: relative;\r\n z-index: 99999;\r\n font-family: Mada,Lato,Helvetica,Arial,Lucida,sans-serif;\r\n}\r\n\r\n.ins1-container.ins1-et_menu_container {\r\n z-index: 99;\r\n}\r\n\r\n\r\n@media (min-width: 981px) {\r\n .ins1-et_fullwidth_nav #ins1-main-header .ins1-container {\r\n width: 100%;\r\n max-width: 100%;\r\n padding-right: 30px;\r\n padding-left: 30px;\r\n }\r\n}\r\n\r\n.ins1-logo_container {\r\n -webkit-transition: all .4s ease-in-out;\r\n transition: all .4s ease-in-out;\r\n max-width: 120px;\r\n}\r\n\r\n.ins1-et_header_style_left .ins1-logo_container {\r\n position: absolute;\r\n height: 100%;\r\n width: 100%;\r\n}\r\n\r\n#ins1-et-info-email, \r\n#ins1-et-info-phone, \r\n.ins1-et-cart-info span {\r\n position: relative;\r\n color: #fff;\r\n}\r\n\r\n#ins1-top-header .ins1-container {\r\n padding-top: 9px;\r\n font-weight: 600;\r\n}\r\n#ins1-et-info-phone {\r\n margin-right: 13px;\r\n}\r\n\r\n#ins1-et-info-phone:before {\r\n content: \\\f095\;\r\n position: relative;\r\n top: 2px;\r\n margin-right: 2px;\r\n font: normal normal normal 14px/1 FontAwesome;\r\n font-size: inherit;\r\n text-rendering: auto;\r\n -webkit-font-smoothing: antialiased;\r\n}\r\n\r\n#ins1-et-info-email:before {\r\n content: \\\f0e0\;\r\n margin-right: 4px;\r\n font: normal normal normal 14px/1 FontAwesome;\r\n font-size: inherit;\r\n text-rendering: auto;\r\n -webkit-font-smoothing: antialiased;\r\n}\r\n\r\n#ins1-top-header, #ins1-top-header a, #ins1-et-secondary-nav li li a, #ins1-top-header .ins1-et-social-icon a:before {\r\n letter-spacing: 2px;\r\n}\r\n\r\nspan.ins1-logo_helper {\r\n display: none;\r\n width: 0;\r\n}\r\n\r\n.ins1-et_menu_container {\r\n display:flex;\r\n align-items:center;\r\n justify-content: space-between;\r\n padding: 22px 20px;\r\n}\r\n\r\n#ins1-logo {\r\n -webkit-transition: all .4s ease-in-out;\r\n transition: all .4s ease-in-out;\r\n margin-bottom: 0;\r\n max-height: 54%;\r\n display: inline-block;\r\n float: none;\r\n vertical-align: middle;\r\n -webkit-transform: translateZ(0);\r\n}\r\n\r\n#ins1-et-top-navigation {\r\n font-weight: 600\r\n}\r\n\r\n.ins1-et_fixed_nav #ins1-et-top-navigation {\r\n -webkit-transition: all .4s ease-in-out;\r\n transition: all .4s ease-in-out\r\n}\r\n\r\n#ins1-et-secondary-menu {\r\n float: right\r\n}\r\n\r\n#ins1-et-info0,\r\n#ins1-et-secondary-menu\u003eul\u003eli a {\r\n padding-bottom: .75em;\r\n display: block\r\n}\r\n\r\n#ins1-et-secondary-nav,\r\n#ins1-et-secondary-nav li {\r\n display: inline-block\r\n}\r\n\r\n#ins1-et-secondary-nav a {\r\n -webkit-transition: background-color .4s,color .4s ease-in-out;\r\n transition: background-color .4s,color .4s ease-in-out\r\n}\r\n\r\n#ins1-et-secondary-nav li {\r\n margin-right: 15px\r\n}\r\n\r\n#ins1-et-secondary-nav\u003eli:last-child {\r\n margin-right: 0\r\n}\r\n\r\n.ins1-et-cart-info span:before {\r\n content: \\\e07a\;\r\n margin-right: 10px\r\n}\r\n\r\n#ins1-top-menu,\r\n.ins1-et-menu,\r\nnav#ins1-top-menu-nav,\r\nnav.ins1-et-menu-nav {\r\n list-style: none;\r\n margin: 0;\r\n}\r\n\r\n#ins1-top-menu li {\r\n display: inline-block;\r\n font-size: 14px;\r\n padding-right: 22px\r\n}\r\n\r\n#ins1-top-menu\u003eli:last-child {\r\n padding-right: 0\r\n}\r\n\r\n.ins1-et_fullwidth_nav.ins1-et_non_fixed_nav.ins1-et_header_style_left #ins1-top-menu\u003eli:last-child\u003eul.ins1-sub-menu {\r\n right: 0\r\n}\r\n\r\n#ins1-top-menu a {\r\n color: rgba(0,0,0,.6);\r\n text-decoration: none;\r\n display: block;\r\n position: relative;\r\n -webkit-transition: all .4s ease-in-out;\r\n transition: all .4s ease-in-out\r\n}\r\n\r\n#ins1-et-info-email:hover,\r\n#ins1-et-secondary-menu\u003eul\u003eli\u003ea:hover,\r\n#ins1-top-menu-nav\u003eul\u003eli\u003ea:hover,\r\n.ins1-et-social-icons a:hover {\r\n opacity: .7; \r\n -webkit-transition: all .4s ease-in-out;\r\n transition: all .4s ease-in-out\r\n}\r\n\r\n#ins1-top-menu a {\r\n color: rgba(0,0,0,.6);\r\n text-decoration: none;\r\n display: block;\r\n position: relative;\r\n -webkit-transition: all .4s ease-in-out;\r\n transition: all .4s ease-in-out;\r\n display: inline-flex;\r\n align-items: center;\r\n font-family: Mada,Lato,Helvetica,Arial,Lucida,sans-serif;\r\n}\r\n\r\n#ins1-et-secondary-nav .ins1-menu-item-has-children\u003ea:first-child:after, \r\n#ins1-top-menu .ins1-menu-item-has-children\u003ea:first-child:after {\r\n font: normal normal normal 10px/1 FontAwesome;\r\n content: \\\f078\;\r\n margin-left:10px;\r\n}\r\n\r\n.ins1-menu-item:hover #ins1-et_mobile_nav_menu {\r\n display: block !important;\r\n}\r\n\r\n.ins1-nav li:hover {\r\n visibility: inherit;\r\n}\r\n\r\n.ins1-nav li {\r\n position: relative;\r\n}\r\n\r\n.ins1-nav li ul {\r\n display:none;\r\n position: absolute;\r\n padding: 20px 0;\r\n width: 240px;\r\n background: #fff;\r\n border-top: 3px solid #2ea3f2;\r\n box-shadow: 0 2px 5px rgb(0 0 0 / 10%);\r\n text-align: left;\r\n}\r\n\r\n.ins1-nav li.ins1-et-touch-hover\u003eul, .ins1-nav li:hover\u003eul {\r\n display:block;\r\n}\r\n\r\n#ins1-top-menu li li a {\r\n padding: 6px 20px;\r\n width: 200px;\r\n}\r\n\r\n.ins1-nav li li ul {\r\n z-index: 1000;\r\n top: -23px;\r\n left: 240px;\r\n}\r\n\r\n#ins1-menu-item-208 {\r\n position: static;\r\n}\r\n\r\nli.ins1-mega-menu#ins1-menu-item-208 \u003eul {\r\n width: auto;\r\n left: 30px!important;\r\n right: 30px!important;\r\n}\r\n\r\n#ins1-menu-item-208:hover \u003e .ins1-sub-menu {\r\n display: flex;\r\n}\r\n#ins1-menu-item-208 \u003e .ins1-sub-menu a:after {\r\n content: !important;\r\n}\r\n\r\n#ins1-top-menu li.ins1-mega-menu li\u003eul {\r\n -webkit-animation: none!important;\r\n animation: none!important;\r\n padding: 0;\r\n border: none;\r\n left: auto;\r\n top: auto;\r\n width: 90%!important;\r\n position: relative;\r\n box-shadow: none;\r\n -webkit-box-shadow: none;\r\n}\r\n\r\n#ins1-top-menu li.ins1-mega-menu li ul {\r\n display:block;\r\n}\r\n\r\n#ins1-menu-item-227 .ins1-sub-menu li ul {\r\n left: auto;\r\n right: 240px;\r\n}\r\n\r\n#ins1-top-menu li.ins1-mega-menu.ins1-mega-menu-parent-3\u003eul\u003eli {\r\n width: 33.33%;\r\n}\r\n\r\nli#ins1-menu-item-225 .ins1-menu-item .ins1-sub-menu {\r\n left: auto;\r\n right: 100%;\r\n}\r\n\r\nli#ins1-menu-item-2220 .ins1-sub-menu {\r\n left: auto;\r\n right: 0;\r\n}\r\n\r\n#ins1-top-menu li.ins1-mega-menu\u003eul\u003eli\u003ea:first-child {\r\n padding-top: 0!important;\r\n font-weight: 700;\r\n border-bottom: 1px solid rgba(0,0,0,.03);\r\n}\r\n.ins1-nav ul li a:hover {\r\n background-color: rgba(0,0,0,.03);\r\n opacity: .7;\r\n}\r\n\r\n/*footer*/\r\n\r\n#ins1-main-footer {\r\n background-color: #222;\r\n font-family: Mada,Lato,Helvetica,Arial,Lucida,sans-serif;\r\n}\r\n\r\n.ins1-et_pb_section_19,\r\n.ins1-et_pb_section_19 h4{\r\n font-family: Mada,Lato,Helvetica,Arial,Lucida,sans-serif ;\r\n}\r\n\r\n#ins1-main-footer {\r\n margin: 0;\r\n}\r\n#ins1-et-footer-nav {\r\n background-color: hsla(0,0%,100%,.05);\r\n}\r\n.ins1-container {\r\n /*width: 80%;*/\r\n /*max-width: 1170px;*/\r\n /*margin: auto;*/\r\n}\r\n\r\n#ins1-top-header, \r\n#ins1-et-secondary-nav li ul {\r\n background-color: #0f4d81;\r\n font-family: Mada,Lato,Helvetica,Arial,Lucida,sans-serif;\r\n}\r\n\r\n@media (min-width: 981px) {\r\n #ins1-top-header .ins1-container {\r\n width: 100%;\r\n max-width: 100%;\r\n padding-right: 30px;\r\n padding-left: 30px;\r\n }\r\n}\r\n\r\n#ins1-top-header, \r\n#ins1-top-header #ins1-et-info, \r\n#ins1-top-header .ins1-container,\r\n#ins1-top-header .ins1-et-social-icon a {\r\n line-height: 12px;\r\n font-size: 12px;\r\n}\r\n\r\n#ins1-et-info,\r\n#ins1-et-secondary-menu\u003eul\u003eli a {\r\n padding-bottom: 9px;\r\n display: block;\r\n}\r\n\r\n\r\n.ins1-bottom-nav {\r\n padding: 15px 0;\r\n display: flex;\r\n}\r\n\r\n.ins1-bottom-nav, .ins1-bottom-nav a {\r\n font-size: 18px;\r\n}\r\n\r\n.ins1-bottom-nav li {\r\n font-weight: 600;\r\n display: inline-block;\r\n font-size: 14px;\r\n padding-right: 22px;\r\n}\r\n\r\n.ins1-bottom-nav li.ins1-current-menu-item\u003ea {\r\n color: #2ea3f2;\r\n}\r\n\r\n.ins1-bottom-nav a:hover {\r\n opacity: .7;\r\n}\r\n\r\n#ins1-footer-bottom {\r\n background-color: rgba(0,0,0,.32);\r\n \r\n padding: 23px 0 5px;\r\n\r\n}\r\n\r\n#ins1-footer-info {\r\n text-align: left;\r\n color: #666;\r\n padding-bottom: 10px;\r\n float: left;\r\n}\r\n\r\n#ins1-footer-info, #ins1-footer-bottom .ins1-et-social-icons {\r\n float: none;\r\n text-align: center;\r\n}\r\n\r\n#ins1-footer-bottom a {\r\n -webkit-transition: all .4s ease-in-out;\r\n transition: all .4s ease-in-out;\r\n}\r\n\r\n#ins1-footer-info a {\r\n font-weight: 700;\r\n color: #666;\r\n}\r\n\r\n.ins1-et_pb_section_19.ins1-et_pb_section {\r\n padding-top: 33px;\r\n padding-right: 0px;\r\n padding-bottom: 0px;\r\n padding-left: 0px;\r\n margin-top: 3px;\r\n background-color: #4d4b50!important;\r\n}\r\n\r\n@media only screen and (min-width: 981px) {\r\n .ins1-et_pb_row_17, \r\n body #ins1-page-container .ins1-et-db #ins1-et-boc .ins1-et-l .ins1-et_pb_row_17.ins1-et_pb_row, \r\n body.ins1-et_pb_pagebuilder_layout.ins1-single #ins1-page-container #ins1-et-boc .ins1-et-l .ins1-et_pb_row_17.ins1-et_pb_row, \r\n body.ins1-et_pb_pagebuilder_layout.ins1-single.ins1-et_full_width_page #ins1-page-container #ins1-et-boc .ins1-et-l .ins1-et_pb_row_17.ins1-et_pb_row {\r\n width: 89%;\r\n max-width: 89%;\r\n }\r\n}\r\n\r\n\r\n.ins1-et_pb_row_17.ins1-et_pb_row {\r\n padding-top: 27px!important;\r\n padding-right: 0px!important;\r\n padding-bottom: 27px!important;\r\n padding-left: 0px!important;\r\n margin-right: auto!important;\r\n margin-left: auto!important;\r\n padding-top: 27px;\r\n padding-right: 0px;\r\n padding-bottom: 27px;\r\n padding-left: 0;\r\n display:flex;\r\n justify-content: center;\r\n}\r\n\r\n@media (min-width: 981px) {\r\n .ins1-et_pb_gutters3 .ins1-et_pb_column, .ins1-et_pb_gutters3.ins1-et_pb_row .ins1-et_pb_column {\r\n margin-right: 5.5%;\r\n }\r\n}\r\n\r\n\r\n@media (min-width: 981px) {\r\n .ins1-et_pb_gutters3 .ins1-et_pb_column_1_4, \r\n .ins1-et_pb_gutters3.ins1-et_pb_row .ins1-et_pb_column_1_4 {\r\n width: 20.875%;\r\n }\r\n}\r\n\r\n\r\n.ins1-et_pb_text_22.ins1-et_pb_text {\r\n color: #bdbfbe!important;\r\n}\r\n\r\n@media (min-width: 981px) {\r\n .ins1-et_pb_gutters3 .ins1-et_pb_column_1_4 .ins1-et_pb_module, \r\n .ins1-et_pb_gutters3.ins1-et_pb_row .ins1-et_pb_column_1_4 .ins1-et_pb_module {\r\n margin-bottom: 13.174%;\r\n }\r\n}\r\n\r\n\r\n.ins1-et_pb_text_inner {\r\n position: relative;\r\n}\r\n\r\n.ins1-et_pb_text\u003e:last-child {\r\n padding-bottom: 0;\r\n}\r\n\r\n.ins1-et_pb_column_1_3 h4,\r\n.ins1-et_pb_column_1_4 h4, \r\n.ins1-et_pb_column_1_5 h4, \r\n.ins1-et_pb_column_1_6 h4,\r\n.ins1-et_pb_column_2_5 h4, \r\n.ins1-et_pb_fullwidth_header_0.ins1-et_pb_fullwidth_header .ins1-header-content h4.ins1-et_pb_module_header {\r\n font-size: 22px!important;\r\n padding-top: 35px;\r\n}\r\n.ins1-et_pb_text_22 h4 {\r\n color: #dbdad9!important;\r\n}\r\n\r\np:not(.ins1-has-background):last-of-type {\r\n padding-bottom: 0;\r\n}\r\n\r\n.ins1-et_pb_bg_layout_light a:link,\r\n.ins1-et_pb_bg_layout_light a:active, \r\n.ins1-et_pb_bg_layout_light a:hover, \r\n.ins1-et_pb_bg_layout_light a:visited, \r\n.ins1-et_pb_bg_layout_light a strong {\r\n color: #ffffff;\r\n text-decoration: underline;\r\n}\r\n\r\nul.ins1-et_pb_social_media_follow {\r\n list-style-type: none!important;\r\n margin: 0 0 22px;\r\n padding: 0;\r\n}\r\n\r\n@media (min-width: 981px) {\r\n .ins1-et_pb_column_single .ins1-et_pb_module.ins1-et-last-child, \r\n .ins1-et_pb_column_single .ins1-et_pb_module:last-child,\r\n .ins1-et_pb_section .ins1-et_pb_row .ins1-et_pb_column .ins1-et_pb_module.ins1-et-last-child, \r\n .ins1-et_pb_section .ins1-et_pb_row .ins1-et_pb_column .ins1-et_pb_module:last-child, \r\n .ins1-et_pb_section.ins1-et_section_specialty .ins1-et_pb_row .ins1-et_pb_column .ins1-et_pb_column .ins1-et_pb_module.ins1-et-last-child, \r\n .ins1-et_pb_section.ins1-et_section_specialty .ins1-et_pb_row .ins1-et_pb_column .ins1-et_pb_column .ins1-et_pb_module:last-child, \r\n .ins1-et_pb_section.ins1-et_section_specialty .ins1-et_pb_row .ins1-et_pb_column .ins1-et_pb_row_inner .ins1-et_pb_column .ins1-et_pb_module.ins1-et-last-child, \r\n .ins1-et_pb_section.ins1-et_section_specialty .ins1-et_pb_row .ins1-et_pb_column .ins1-et_pb_row_inner .ins1-et_pb_column .ins1-et_pb_module:last-child {\r\n margin-bottom: 0;\r\n } \r\n}\r\n\r\n.ins1-et_pb_social_media_follow li.ins1-et_pb_social_media_follow_network_0 {\r\n text-decoration: none;\r\n}\r\n\r\n.ins1-et_pb_social_media_follow_network_0 a.ins1-icon {\r\n background-color: #bdbfbe!important;\r\n}\r\n\r\n.ins1-et_pb_social_media_follow li a.ins1-icon {\r\n height: 32px;\r\n width: 32px;\r\n padding: 0;\r\n -webkit-box-sizing: content-box;\r\n box-sizing: content-box;\r\n}\r\n\r\n.ins1-et_pb_social_media_follow li a.ins1-icon {\r\n border-radius: 3px;\r\n}\r\n\r\n.ins1-et_pb_social_media_follow_0 li a.ins1-icon {\r\n height: 35px;\r\n width: 35px;\r\n}\r\n\r\n.ins1-et_pb_social_media_follow li a.ins1-icon:before {\r\n height: 32px;\r\n width: 32px;\r\n font-size: 16px;\r\n line-height: 32px;\r\n display: block;\r\n color: #fff;\r\n transition: color .3s;\r\n -moz-transition: color .3s;\r\n -webkit-transition: color .3s;\r\n position: relative;\r\n z-index: 10;\r\n}\r\n\r\n\r\n.ins1-et_pb_social_media_follow_0 li a.ins1-icon:before {\r\n font-size: 17px;\r\n line-height: 35px;\r\n height: 35px;\r\n width: 35px;\r\n}\r\n\r\n.ins1-et_pb_social_media_follow .ins1-et_pb_social_media_follow_network_0.ins1-et_pb_social_icon .ins1-icon:before {\r\n color: #4d4b50;\r\n}\r\n\r\n.ins1-et_pb_social_media_follow_network_name {\r\n display: none;\r\n}\r\n\r\n@media (min-width: 981px) {\r\n .ins1-et_pb_column_1_4, \r\n .ins1-et_pb_row .ins1-et_pb_column_1_4 {\r\n width: 20.875%;\r\n } \r\n}\r\n\r\n.ins1-et_pb_text_23 h4,\r\n.ins1-et_pb_text_24 h4{\r\n color: #dbdad9!important;\r\n}\r\n\r\n.ins1-et_pb_text_inner p {\r\n padding-bottom: 17px;\r\n}\r\n\r\n.ins1-et_pb_text_23.ins1-et_pb_text {\r\n color: #bdbfbe!important;\r\n}\r\n\r\n\r\n.ins1-et_pb_image_9 {\r\n background-color: #ffffff;\r\n padding-top: 15px;\r\n padding-right: 15px;\r\n padding-bottom: 15px;\r\n padding-left: 15px;\r\n text-align: center;\r\n},customHeaderHtml:null,excludedClasses:,customCss:\.main-content #products-block .products-list li h3 a{display:block;}\,javascriptCode:\u003cscript\u003e\r\n // $(function() {\r\n // function waitForEl(selector, callback) {\r\n // if (jQuery(selector).length) {\r\n // callback();\r\n // } else {\r\n // setTimeout(function() {\r\n // waitForEl(selector, callback);\r\n // }, 100);\r\n // }\r\n // };\r\n\r\n\r\n // $(\\u003cdiv\u003e\)\r\n // .addClass(container)\r\n // .addClass(ins1-banner)\r\n // .append($(\.banner-header a.visible-lg\))\r\n // .insertBefore(.ins1-secondary-and-action);\r\n // $(.ins1-banner img).css(width, 100%);\r\n\r\n\r\n // waitForEl(\.top-banner a.visible-lg\, function() {\r\n // $(\.ins1-banner\).append($(\.top-banner a.visible-lg\));\r\n // });\r\n // $(.ins1-secondary-and-action).remove();\r\n // }); \r\n\u003c/script\u003e},organizedArticles:,sponsoredArticles:{articleType:7,previewText:Empower vascular access teams with tools that streamline workflows, enhance teamwork, and improve outcomes.,relevancy:1,approvalType:0,language:en,companyName:Salubrity Online,companyId:18370,isCompanyApproved:0,isCompanyActive:1,subTitle:,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2025-01-07T14:24:00.333,companyLogoUrl:companies/5f2ab040-89ac-4fab-b30a-64d10eff7a68.jpg,companyLogoDominantColor:null,publishedRank:0,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:0,labelsCount:0,additionalData:null,contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:null,allArticlesApproved:0,companySiteUrl:https://salubrityonline.com/?utm_sourcereferer\u0026utm_mediumemail\u0026utm_campaignemail_sig,isManualOrdering:false,layoutId:0,articleId:914,statusId:1,thumbnailUrl:advertisements/d1f3c34e-1bb1-4665-bad8-430c4cab31a7.png,publicationDate:2025-01-07T00:00:00,title:Tools for Efficient Vascular Access | Salubrity Online,openMode:1,uri:https://linkshandler.caboodleai.net/c40c0a172dab42768cd77138dafbd13b,domainUrl:null,isSponsored:true,articleUrl:https://linkshandler.caboodleai.net/c40c0a172dab42768cd77138dafbd13b},{articleType:7,previewText:Unlock vital skills to safely administer antineoplastic therapy with gold-standard education. ,relevancy:1,approvalType:0,language:en,companyName:Oncology Nursing Society | ONS | ons.org,companyId:18357,isCompanyApproved:0,isCompanyActive:1,subTitle:,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2024-12-05T22:19:10.753,companyLogoUrl:companies/e5f18947-4c9e-47b2-9534-5379c06c2e2a.org.png,companyLogoDominantColor:null,publishedRank:0,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:0,labelsCount:0,additionalData:null,contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:null,allArticlesApproved:0,companySiteUrl:ons.org,isManualOrdering:false,layoutId:0,articleId:907,statusId:1,thumbnailUrl:advertisements/e7898301-3c14-4ed0-85fd-2ee432e4abbe.png,publicationDate:2025-01-01T00:00:00,title:ONS Provides Valuable Knowledge and Resources Developed for Nurses by Nurses ,openMode:1,uri:https://linkshandler.caboodleai.net/ace5a1caff4044d98ccfed27735fa553,domainUrl:null,isSponsored:true,articleUrl:https://linkshandler.caboodleai.net/ace5a1caff4044d98ccfed27735fa553},{articleType:7,previewText:AVA Consensus Statement recommend adhesives like gum mastic to secure PIVC dressings and devices.,relevancy:1,approvalType:0,language:en,companyName:Eloquest Healthcare,companyId:10589,isCompanyApproved:0,isCompanyActive:1,subTitle:,labels:null,entities:null,userEntities:null,isPinned:false,createDate:2024-11-22T15:33:38.807,companyLogoUrl:companies/2d76b2e3-da99-4333-a870-a052f5290c1b.com.png,companyLogoDominantColor:null,publishedRank:0,attachmentName:null,attachmentUrl:null,relevancyRank:0,numberOfVideos:0,idRowNum:0,labelsCount:0,additionalData:null,contentHtml:null,reads:0,facebookShare:null,twitterShare:null,linkedInShare:null,userId:0,userName:null,shortLink:null,shareDate:0001-01-01T00:00:00,sourceType:0,creatorUserName:null,articlePlateType:null,allArticlesApproved:0,companySiteUrl:,isManualOrdering:false,layoutId:0,articleId:905,statusId:1,thumbnailUrl:advertisements/f655cd21-3aaa-4e9e-b39e-466d6424c40d.png,publicationDate:2025-01-01T00:00:00,title:New Standard in PIVC Securement: Evidence Highlights Key Role of Additional Adhesives for Success,openMode:1,uri:https://linkshandler.caboodleai.net/81b0d3cc3a364ff79de0b8b55bbd5544,domainUrl:null,isSponsored:true,articleUrl:https://linkshandler.caboodleai.net/81b0d3cc3a364ff79de0b8b55bbd5544},siteFeatures:{featureId:7,featureName:CampaignMailjetQueue,featureStatusId:1},{featureId:8,featureName:DistributionsPullRefresh,featureStatusId:1},{featureId:14,featureName:SingleAnalyticsStats,featureStatusId:1},{featureId:15,featureName:UseMenuLabelsOption,featureStatusId:1},{featureId:20,featureName:NewSimilarity,featureStatusId:1},{featureId:24,featureName:NewSearchResult,featureStatusId:1},{featureId:25,featureName:NewCampaignStatistics,featureStatusId:1},{featureId:26,featureName:NewRelevancy,featureStatusId:1},{featureId:27,featureName:NewPortalTogglingIsEnabled,featureStatusId:1},{featureId:29,featureName:UseNewLinksHandler,featureStatusId:1},{featureId:31,featureName:NewLogReadArticle,featureStatusId:1},{featureId:34,featureName:SendCampaignAsHtml,featureStatusId:1},{featureId:36,featureName:NewTemplateParsing,featureStatusId:1},{featureId:47,featureName:NewBuyersGuidePage,featureStatusId:1},{featureId:59,featureName:NewAkamaiCredentials,featureStatusId:1},siteProducts:{productId:1,productCode:NF,productName:Newsfeed,productUrl:/newsfeed,description:null},{productId:2,productCode:NL,productName:Newsletters,productUrl:/newsletters,description:null},{productId:3,productCode:ID,productName:Industry Directory,productUrl:/companies,description:null},{productId:4,productCode:Ads,productName:Advertisements,productUrl:/manage-my-ads,description:null},meta:{title:INS,description:The #1 newsfeed for the {0} industry. Bringing you the best content from thousands of sources, covering product, research, trends, and more. Pick your industry interests and stay up-to-date with the most relevant news to your business.,host:ins1.caboodleai.net,image:https://media.caboodleai.net/ins1/general/74c824493f794bd89c4c55e35976b27a-01a384a4dcd44bfab356e227683235dc-INS_New_Header__LOGO-165X63.jpg},siteLayout:Default,defaultImagesList:},__N_SSP:true},page:/,query:{},buildId:1734289630900,isFallback:false,dynamicIds:29731,47365,9345,62546,62894,94843,89703,74123,gssp:true,locale:en,locales:en,defaultLocale:en,scriptLoader:}/script>/body>/html>
Subdomains
Date
Domain
IP
media-aws01.caboodleai.net
2024-08-18
104.70.127.178
ins1.caboodleai.net
2025-01-26
23.38.191.178
media-aws03.caboodleai.net
2024-06-27
23.216.145.4
api-aws03.caboodleai.net
2025-01-26
23.38.191.160
bspoke365.caboodleai.net
2024-09-07
23.216.145.4
gcca.caboodleai.net
2024-09-03
23.216.145.4
media.caboodleai.net
2024-07-25
23.216.145.11
apwa.caboodleai.net
2024-02-28
104.70.127.133
asapnewsfeed.caboodleai.net
2021-02-22
184.28.50.33
autoresource.caboodleai.net
2024-07-18
23.216.145.11
ame.caboodleai.net
2024-05-09
23.216.145.11
www.ame.caboodleai.net
2024-09-01
23.216.145.11
architecture.caboodleai.net
2024-07-20
23.216.145.4
offsite.caboodleai.net
2024-09-13
23.216.145.4
earchive.caboodleai.net
2024-07-03
23.216.145.11
civilengineering.caboodleai.net
2024-07-09
23.216.145.11
www.contentmarketing.caboodleai.net
2024-11-17
23.41.4.76
busworldorg.caboodleai.net
2024-08-12
104.96.163.148
biotech.caboodleai.net
2024-06-30
23.55.167.33
dhi.caboodleai.net
2024-02-27
104.96.163.214
100percentoptical.caboodleai.net
2024-02-12
23.216.145.68
portal.caboodleai.net
2024-05-09
23.216.145.13
mail.caboodleai.net
2024-05-09
23.41.4.75
l-ten.caboodleai.net
2024-08-13
23.216.145.4
digitalconstruction.caboodleai.net
2024-07-06
23.216.145.11
asap.caboodleai.net
2024-09-17
23.216.145.11
linkshandler.caboodleai.net
2024-08-26
104.70.127.178
adcampaigns.caboodleai.net
2024-07-16
23.216.145.4
associations.caboodleai.net
2024-09-09
23.216.145.11
exhibitions.caboodleai.net
2024-09-04
23.216.145.11
athletictrainers.caboodleai.net
2024-01-28
104.123.69.161
buildersmerchants.caboodleai.net
2024-09-24
23.41.4.69
facilitiesmanagement.caboodleai.net
2024-06-16
23.216.145.11
chargingpiont.caboodleai.net
2024-08-28
23.216.145.76
thecakeandbakeshow.caboodleai.net
2024-09-10
23.41.4.69
buildersshow.caboodleai.net
2024-08-12
104.96.163.148
housebuildersbuzz.caboodleai.net
2024-09-11
23.41.4.69
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]